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ABSTRACT 
Senecavirus A (SVA) is a nonenveloped, single-stranded, positive-sense RNA virus in 
the family Picornaviridae. It was first discovered as a cell culture contaminant in 2002 but had 
been identified in US swine samples dating back to the late 1980s. Since swine were presumed to 
be the natural host, pigs were experimentally inoculated, but did not develop any specific clinical 
disease. Prior to 2015, SVA was sporadically detected in US swine associated with various 
clinical histories. In 2015, cases of vesicular disease and increased neonatal mortality were 
observed in Brazil and subsequently in the US. SVA was consistently detected in affected 
animals. Although previous attempts to reproduce disease with SVA in the past were 
unsuccessful, experimental inoculation studies performed with contemporary isolates 
demonstrated SVA was a causative agent for vesicular disease in swine.  
SVA is now included in the differential list of etiologic agents that can cause vesicular 
disease in swine. This list includes foot-and-mouth disease virus (FMDV), which is a notifiable 
disease, so when vesicular lesions are observed in FMDV-free countries an investigation must be 
initiated to rule out FMDV. SVA has now been found across the Americas and Asia, and it 
appears the ecology of this virus has changed from sporadic infections to an endemic disease that 
does not induce severe clinical disease; but, its presence does have a significant impact since 
each case needs to be investigated as if it was a FMDV case. Thus, control and prevention 
measures are critical to reducing the spread of SVA in the global swine industry.  
Due to the difficulty of reproducing clinical disease in past experimental challenges and 
the timing of SVA outbreaks in the field with stressful situations, there was speculation that 
stress may be a factor in the development of vesicular lesions. To study the impact of stress, an 
immunosuppressive dexamethasone regime prior to SVA inoculation was administered. Clinical 
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presentation and infection dynamics were similar in pigs treated with dexamethasone and those 
not treated prior to challenge. Another hypothesis for the lack of lesions in early experimental 
challenges was older isolates were less pathogenic than contemporary isolates. Vesicular lesion 
development and viral shedding in swine were compared between three SVA strains isolated 
prior to the 2015 outbreak and three strains isolated during 2015. The majority of animals in all 
groups developed vesicular lesions, and serum had cross neutralizing titers against all viruses. 
Sequencing and analysis of isolates used in the study found amino acid differences between the 
isolates in prominent loop structures of the capsid that may be involved with virus receptor 
binding and host immune response. 
Due to the clinical similarities between SVA and FMDV, control and prevention of SVA 
infections are a priority. Understanding the minimum infectious dose (MID) of SVA could 
provide insights into the infectivity of virus found in the environment and how the virus is 
spread. Finishing pigs and neonates were used to determine the MID of a 2011 SVA isolate 
using intranasal and oral challenge routes respectively. In this study, finishing pigs had a MID of 
103.1 TCID50/mL and neonates 102.5 TCID50/mL. Although there were differences in infectious 
dose, fewer dilutions were tested in finishing pigs, which may provide a less precise estimate 
compared to the neonates. Another control measure for SVA could be vaccination. An 
inactivated vaccine was tested in weaned pigs and mature sows. The vaccine prevented the 
development of clinical signs and viremia as well as reduced rectal shedding in pigs. In addition, 
piglets suckling immunized dams had sterilizing immunity against SVA challenge. Overall, a 
better understanding of the pathogenesis of SVA in swine can help improve control and 
prevention measures to reduce the burden of SVA infection on the swine industry.  
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CHAPTER 1.    GENERAL INTRODUCTION  
Background 
The family Picornaviridae is a large family of RNA viruses consisting of over fifty 
genera that are capable of infecting many species of veterinary importance (ICTV 2019) (1). 
There are limited reports of picornavirus infection in companion animals, but there is a long 
history of picornaviruses in livestock species (2, 3). In 1897, Loeffler and Frosch discovered a 
filterable agent caused foot-and-mouth disease (FMD) in cattle, which was the first description 
of an animal virus, foot-and-mouth disease virus (FMDV) (4-6). Disease manifestation from 
picornavirus infection in livestock can include a wide range of clinical signs including those 
involving the central nervous system (porcine teschovirus), digestive system (bovine 
enterovirus), and respiratory tract (equine rhinitis virus) (7-11). In addition, there is large 
diversity in disease severity caused by infections (12). Though some picornaviruses can cause 
significant clinical disease, due to their ubiquitous prevalence, a majority of infections are 
asymptomatic (7).  
Swine can be infected by several viruses found in the family Picornaviridae (13). Two of 
these viruses, FMDV and swine vesicular disease virus (SVDV), cause clinically identical 
vesicular disease, which involves blister-like lesions that form on the coronary bands and snout. 
Porcine enteroviruses circulate worldwide in domestic pigs, and infections are often 
asymptomatic; but, depending on the virus serotype and conditions of infection, they can cause 
clinical signs including neurologic disorders, reproductive failure, and enteric disease (14). Due 
to the diversity of porcine enteroviruses, they have now been reorganized into three genera 
within the family Picornaviridae: Enterovirus, Teschovirus, and Saplovirus (15). A recent 
addition to the picornavirus family that infects swine was named Senecavirus A (SVA), which is 
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the only member of the genus Senecavirus and shares closest sequence identity to the genomes 
of those viruses in the Cardiovirus genus (16).  
SVA was originally identified as a cell culture contaminant, but subsequent research has 
demonstrated SVA to be a causative agent for vesicular disease in swine, which is clinically 
identical to FDMV and SVDV (16, 17). In countries participating in the World Health 
Organization (OIE), FMDV is a reportable agent. The US is FMDV-free and when a vesicle is 
observed in livestock, a foreign animal disease (FAD) investigation must be initiated to rule out 
FMDV. Since the discovery of SVA in the US, it has been identified in other countries including 
Brazil, Canada, and China (18-20). Understanding the pathogenesis of SVA and molecular 
evolution can aide in the development of control measures to prevent further spread of the virus.   
Research Objectives 
Unsuccessful attempts to reproduce clinical disease experimentally and isolation of SVA 
from asymptomatic animals led to questions about why some animals develop vesicular lesions 
and others do not (21, 22). Hypotheses have included pathogenicity differences between SVA 
strains, host factors, and the requirement of a co-factor (23). Vesicular disease in the field due to 
SVA often coincided with stressful scenarios, such as marketing of finishing hogs and parturition 
at sow farms. Thus, research was performed to determine the role of stress in SVA clinical 
disease progression and infection dynamics in nursery pigs. To test the hypothesis of 
pathogenicity differences in SVA isolates, three historical and three contemporary isolates were 
chosen for an animal study. Vesicular lesion development, viremia, and viral shedding in oral 
and rectal swabs was compared between groups. Serum collected from pigs at necropsy was also 
used to analyze cross-neutralizing titers against all isolates. Finally, sequences were analyzed for 
differences in prominent loops of the structural proteins involved with receptor binding. 
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Sow slaughter facilities have continued to be a source of FAD investigations due to 
vesicular lesion detection. Co-mingling of animals from different sources and passing them 
through continuous flow buying stations may be contributing to virus transmission and chronic 
reporting of vesicular cases (24). Understanding the infectious dose of SVA and viral load in the 
environment could help direct efforts to reduce virus transmission. This work used a 2011 SVA 
isolate to determine the minimum infectious dose in both finishing pigs and neonates. Another 
goal was to correlate polymerase chain reaction (PCR) cycle threshold (Ct) values to virus 
titration in cell culture, which can aide in interpretation of environmental samples and the 
effectiveness of cleaning and disinfection procedures. Vaccines also play a crucial role in disease 
management in swine. The final objective of this work was to evaluate the efficacy of an 
inactivated SVA vaccine in both weaned pigs and sows. In addition, passive maternal immunity 
was tested by challenging piglets suckling immunized dams.  
Implications 
Knowledge about the pathogenesis of SVA in swine can provide many benefits to the 
swine industry. Understanding how long the virus can be detected in various sample types after 
infection can aide in choosing the correct samples to collect for diagnosis. In addition, 
determining the infectious dose of SVA and the duration of virus shedding can help determine 
measures to control virus spread between animals. Prevention of SVA infection and disease with 
an efficacious vaccine would improve swine welfare, minimize SVA transmission, and reduce 
the burden of FAD investigations.      
Dissertation Organization 
This dissertation contains seven chapters. Chapter 1 is a general introduction and 
rationale for the research performed. Chapter 2 is a literature review of Senecavirus A (SVA). 
Chapter 3 is a modified manuscript published in BMC Veterinary Research studying the effect of 
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stress on SVA infection dynamics and vesicular lesion development by comparing pigs treated 
with an immunosuppressive dexamethasone regime prior to SVA inoculation to pigs that were 
not treated prior to challenge. Chapter 4 is a modified manuscript that is under review in 
Veterinary Microbiology comparing SVA infection dynamics of three historical SVA isolates 
collected prior to 2015 and three contemporary isolates from 2015 and the cross-neutralizing 
antibody titers. In addition, nucleotide sequences from the isolates were compared and predicted 
amino acid sequence differences from significant loop structures on the capsid were analyzed. 
Chapter 5 is a manuscript prepared for submission to PLoS One reporting the minimum 
infectious dose of SVA required to infect finishing pigs and neonates. Chapter 6 is a manuscript 
prepared for submission to Vaccines evaluating the efficacy of a whole-virus SVA inactivated 
vaccine against SVA challenge in weaned pig and sows. Passive maternal immunity provided by 
vaccinated sows was also tested by piglet challenge. Chapter 7 summarizes the research in this 
dissertation and its implications, as well as future directions for research. 
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CHAPTER 2.    LITERATURE REVIEW 
Picornavirus Biology 
Picornaviruses are small, non-enveloped, single-stranded, positive sense RNA viruses 
with genomes ranging from approximately 7 to 10 kilobases (kb) (1). The 5’ untranslated region 
(UTR) links to a small peptide VPg, which acts as a primer during RNA synthesis, and the 3’ 
UTR is followed by a polyA tail (2, 3). Both UTRs have significant secondary structures with the 
5’UTR containing an internal ribosome entry site (IRES), which is critical to initiate cap-
independent translation required by picornaviruses (4, 5). In between the 5’ and 3’ UTRs lies a 
single open reading frame (ORF) encoding a polyprotein processed post-translationally by viral 
proteases into four structural proteins (VP1, VP2, VP3, and VP4) and seven nonstructural 
proteins (2A, 2B, 2C, 3A, 3B, 3Cpro, 3Dpol) (6). Some genera also contain the Leader protein 
(L-pro), thus resulting in the conserved picornavirus L-4-3-4 layout, with the structural proteins 
followed by the nonstructural proteins (7). They have an icosahedral capsid approximately 30 nm 
in diameter that is composed of 60 protomers made up of each of the four structure proteins 
(VP1, VP2, VP3, and VP4) (8). VP1-3 reside on the outer surface of the capsid with VP4 located 
internally (9, 10). L-pro, 2A, and 3Cpro are viral proteases involved in cleaving both the viral 
polypeptide as well as host proteins (9). 
To gain entry into the cell, picornaviruses bind to a cell surface receptor, which leads to 
receptor mediated endocytosis (10, 11). Subsequent destabilization of the capsid, through the 
loss of VP4 and creation of a channel thought to involve VP1, leads to the release of the genome 
from the acidic environment of the endosome into the cytoplasm (8, 12). Since the genome is 
positive sense, translation can begin immediately to produce mature viral proteins (5). 
Eventually, there is a transition from translation to transcription, and genome replication by the 
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RNA-dependent RNA polymerase (RdRP, 3Dpol) occurs in viral replication complexes formed 
by viral modification of host cell membranes (13). Replication starts with negative strand 
synthesis that serves as a template for positive strand synthesis, which can be used for further 
protein synthesis or be packaged into new virions. VP0, the precursor of VP4 and VP2, along 
with VP1 and VP3, form protomers and pentamers that come together with the viral genome to 
form the provirion (14). The final step of virion formation involves the cleavage of VP0 into 
VP4 and VP2, which is suspected to be autocatalytic (15, 16). This process has been reported to 
change the capsid conformation and is critical for an infectious mature virion (17). Mature 
virions are typically thought to be released through cell lysis, but recent work has also shown 
viruses escaping via lipid membrane enclosed particles or vesicles (18, 19). 
Type 1 interferons are an important part of the innate immune response to control 
picornavirus infection as well as neutralizing antibodies from the adaptive immune response 
(20). Picornaviruses have evolved many mechanisms to counteract and evade these host immune 
responses. Viral proteases have been shown to suppress interferon (IFN) production and block 
IFN induction of interferon-stimulated genes (ISGs), thus inhibiting the early steps of the innate 
immune response (21). Interference with host pathogen recognition receptors (PRRs), like 
retinoic acid-inducible protein 1 (RIG-1), has also been reported; and without innate immune 
recognition, the more specific adaptive immune response is delayed (22). Picornaviruses are 
known for the rapid shutdown of host translation, resulting in the preferential translation of viral 
RNA and reduced cellular transcription (20, 23). They are also known to modulate cellular 
pathways for apoptosis and autophagy to promote viral replication and dissemination (11). 
Finally, the low fidelity and absence of excision activity for proofreading of picornavirus RdRPs 
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can result in higher mutation rates and the ability to more rapidly adapt to defenses mounted by 
the host (24).    
Senecavirus A Biology 
As a member of the family Picornaviridae, SVA has one ORF encoding a large 
polyprotein that is then cleaved into 12 mature proteins in the standard picornavirus L-4-3-4 
layout (25). The three major protein regions are P1 (VP1, VP2, VP3, and VP4), P2 (2A, 2B, 2C), 
and P3 (3A, 3B, 3C, 3D) (26). The single ORF is flanked by a long 5’UTR (666 residues) and 
short 3’UTR (71 residues) followed by a poly(A) tail resulting in a genome ~7.3 kb (27). SVA 
has a type IV IRES in the 5’UTR with a predicted secondary structure most closely related to 
classical swine fever virus (CSFV) (28). There is evidence that IRES elements can move 
between genomes, thus leading to speculation of recombination during a co-infection event of 
CSFV and SVA in swine (28, 29).  
The capsid consists VP1, VP2, VP3, and VP4 with lengths of 265, 286, 241, and 74 
residues, respectively (30). Prominent loop structures in the structural proteins of the capsid for 
SVA have been identified: BC loop of VP1 (residues 50-74), Loop II or CD loop of VP1 
(residues 94-109), GH loop of VP1 (residues 185-215), “the puff” of VP2 (residues 172-200), 
and “the knob” of VP3 (residues 57-73) (30). These structures on the capsid can help determine 
cell tropism as well as antigenic sites that elicit immune responses to infection (31). Anthrax 
toxin receptor 1 (ANTXR1), also known as tumor endothelial marker 8 (TEM8), has been 
demonstrated to be a receptor for SVA interacting mainly with the BC loop and Loop II of VP1, 
“the puff” of VP2, and “the knob” of VP3 (32-34). Binding of the virus to the receptor causes 
structural changes in both VP1 and VP3 (35). In addition, multiple linear B-cell epitopes have 
been identified for both VP1 and VP2 (36).  
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The functions of the nonstructural proteins have mostly been assumed, based on 
knowledge gained from past picornavirus research. For example, 2A has a predicted ribosome-
skipping function, and 2C is similar to a helicase that assists with RNA synthesis (37). Other 
proteins, including 3C and 3D, have more conserved motifs with other known picornaviruses 
serving as a proteinase and RdRP, respectively (38). Fortunately, research groups have 
successfully generated infectious cDNA clones of full-length wild-type SVA from both the 
United States (US) and China (39-41). A reverse genetics system has many benefits including 
further characterization of SVA biology and pathogenesis, as well as vaccine development (39, 
40). In addition, SVA has been found to replicate in multiple cell lines, such as swine testicular 
(ST) cells, porcine kidney cells, baby hamster kidney cells, and a multitude of human cancer 
cells lines (e.g. H1299) thus making the virus easy to work with in cell culture (42, 43).  
Cells generate a type 1 IFN response as a first line of defense against SVA infection, and 
SVA has shown sensitivity to IFN-β (44-46). RIG-1, a PRR, was shown to be essential to 
activate the type 1 IFN cascade in SVV infected cells (46). To combat this, 2C and 3C induce the 
degradation of RIG-1, subsequently reducing IFN-β production (47). 3CPro protease activity, 
including reducing interferon regulatory factor (IRF) 3 and IRF7 protein levels and 
deubiquitinating activity, helps SVA evade the host type 1 interferon response by reducing the 
transcription of IFN-β, IFN-α, and ISG54 (48, 49). In addition, 3Cpro cleaves host adapters, 
including mitochondrial antiviral signaling (MAVS), which also leads to the disruption of PRR-
mediated IFN production (45). Finally, 3CPro was also associated with the cleavage of nuclear 
factor-kappa B (NF-κB), along with 2C activating caspase-3, suggesting viral involvement in 
promoting cellular apoptosis for dissemination of virus (50, 51). Additional work in cell culture 
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has demonstrated SVA induces autophagy to promote virus production, and exosomes can 
mediate intercellular transmission for viral spread (52, 53). 
 One interesting aspect of SVA biology is its cytolytic potential in neuroendocrine and 
pediatric tumors (54, 55). Cell lines from small-cell lung cancer (SCLC) and solid pediatric 
cancer were 10,000-fold more sensitive to SVA cytolytic activity than cell lines from normal 
human tissue (54). TEM8 is upregulated in some tumor cell populations, which could explain 
SVA selectivity for infecting tumor cells (33). Initial studies using mice as human models 
showed promise in treating SCLC, medulloblastoma, retinoblastoma, and pediatric malignant 
glioma (56-59). The oncolytic virus was moved forward to Phase 1 trials to treat neuroendocrine 
tumors in both adults and children; although there was evidence of antitumor activity, 
neutralizing antibody production may limit utility (60, 61). Phase II trials in adults with late-
stage SCLC did not benefit from treatment (62).  
Clinical History 
SVA was first discovered in 2002 at a laboratory in Maryland as a cell culture 
contaminant in PER.C6 cells and was named Seneca Valley virus-001 (SVV-001) (25). It was 
speculated the contamination could have been introduced by either porcine trypsin or fetal 
bovine serum, both commonly used in cell culture (54). The National Veterinary Services 
Laboratory isolated twelve picornavirus-like viruses between 1988 and 2005 from swine 
exhibiting a variety of clinical signs and from multiple states across the US (63). Sequencing 
highlighted the close relationship of these isolates with SVV-001, and neutralizing antibodies 
were found in swine serum samples supporting swine as a natural host. Interestingly, serum 
samples from cattle also had neutralizing antibodies (63). Two of these historical isolates were 
used to inoculate pigs, but they did not develop any specific clinical disease (63).  
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Market weight pigs being transported from Canada to the US in 2007 arrived with a 
majority of animals presenting with lameness and some with vesicular lesions on the snouts and 
coronary bands (64). Samples from these animals were tested for the top differentials for swine 
vesicular disease: FMDV, SVDV, vesicular stomatitis (VS), and vesicular exanthema of swine 
(VES). Results were negative, so the animals were diagnosed with idiopathic vesicular disease 
(IVD), though samples from these animals did test positive for SVA by reverse transcriptase 
polymerase chain reaction (RT-PCR) (64). Subsequently, a boar in Indiana that had vesicular 
lesions in the oral cavity, on the snout, and on the coronary bands tested positive for SVA (65). 
Since SVA had also been found in healthy swine, the case was also considered IVD. Due to 
evidence that SVA infected swine, Yang et al. developed a competitive enzyme-linked 
immunosorbent assay (ELISA) tested using serum generated from experimentally inoculated 
pigs (42). Inoculated pigs did not develop clinical disease, though they did generate an antibody 
response. Thus, experimental infection with SVA failed to reproduce any consistent clinical 
disease, but evidence from field cases supported an association of SVA infection with vesicular 
disease in swine.   
Beginning in late 2014, reports of vesicular lesions in swine, along with an increase in 
neonatal mortality observed in piglets less than a week of age, were spreading across the swine 
producing regions of Brazil (66). The mortality observed in the piglets was given the name 
epidemic transient neonatal losses (ETNL), and piglets displayed inconsistent clinical signs prior 
to death including lethargy, wasting, neurologic signs, and diarrhea (66). Samples collected from 
these cases tested negative for the classical causes of vesicular disease in swine but did test 
positive for SVA (67). In the summer of 2015, similar cases of vesicular disease were observed 
in swine in the US that also tested positive for SVA with a 97.7-98.0% nucleotide identity to the 
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isolates from Brazil (68, 69). In addition, there were similar reports of ETNL at sow farms 
experiencing outbreaks of SVA and vesicular disease (70).  
Overwhelming evidence from the field supported SVA as a causative agent for vesicular 
disease in swine; however, prior to these outbreaks, no group had been able to produce specific 
clinical disease after experimental inoculation. Two groups used a 2015 SVA strain isolated from 
a vesicular disease case in finishing pigs from South Dakota and were able to experimentally 
induce vesicular lesions on coronary bands and the snouts of both 9-week-old pigs (71) and 15-
week-old pigs (72). In addition, another group using a different 2015 SVA isolate was able to 
reproduce vesicular lesions in 3-week-old pigs (41). Thus, there now was evidence, both 
experimentally and from the field, that SVA is a causative agent for vesicular disease in swine. 
Since multiple groups were able to experimentally reproduce disease, questions remain as to why 
previous attempts with historical isolates were unsuccessful. Some areas of speculation include 
differences in pathogenicity of viruses, susceptibility of the host, or the requirement of a novel 
co-factor. 
Epidemiology 
Shortly after the 2015 outbreak began, a diagnostic laboratory from the US tested oral 
fluids from 441 sample submissions representing 25 states and 5 samples tested PCR positive for 
SVA equaling an incidence of ~1% (73). During 2017, 444 diagnostic submission samples 
(serum, swabs, oral fluids, and tissues) reported a 5.4% positive rate; but if the 225 serum 
samples were removed, the positive rate increased to 10.5% (74). In addition, prevalence of SVA 
antibodies in swine was measured from samples collected in 2016 from 3,654 growing pigs and 
2,433 sows using both an ELISA and immunofluorescence assay (IFA). They estimated the 
seroprevalence of growing pigs was 12.2% and of sows was 34% (75). Scientists in Brazil 
compared seroprevalence of antibodies against SVA in serum samples collected prior to the 
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outbreaks in 2014/2015 and after those outbreaks. Samples prior to the outbreak were negative 
for antibodies while 34.6% of post-outbreak samples were positive, supporting that SVA had not 
been circulating in Brazil prior to 2014 and that seroprevalence was similar to sow farms in the 
US (76).   
Although the first SVA cases reported in the US in the summer of 2015 involved pigs 
from county fairs and late finishing pigs in the Midwest, the virus was also quickly identified at 
sow farms reporting increases of neonatal mortality ranging from 30-70% along with a diverse 
range of adult animals exhibiting vesicular disease (77). One study reported that 2/6 SVA-
affected breeding herds did not report vesicular lesions in sows (78). In Brazil similar findings 
were reported consisting of neonatal mortality ranging from 5-60% and mixed reports on the 
number of affected farms that also observed vesicular lesions on the sows (38). A study 
comparing clinically affected sows to non-clinically affected sows on a sow farm experiencing 
an SVA outbreak demonstrated similar PCR positive samples and antibody responses between 
both groups (79). Therefore, not all animals infected with the virus develop vesicular disease and 
affected farms may be under reported, thus contributing to the spread of SVA.  
Epidemiologic investigations assigned employee entry, carcass disposal, and cull sow 
removal as high-risk events for SVA introduction to a farm, but also mentioned rodents, feed 
delivery, and semen entry as high risk (78). Live virus has been isolated from environmental 
samples (e.g. dust on fans, farm hallways, the ground outside, and a mortality tractor bucket), 
mouse feces, and mouse small intestine from an affected farm; but it was also detected via PCR 
in flies collected from both affected and unaffected farms, thus providing evidence that these 
pests could play a role in the spread of SVA between farms (80). Recently, feed has been 
suspected as a vector to transport virus between countries (81, 82). Dee et al. demonstrated that 
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SVA remained infectious in most feed ingredients tested in a simulated Trans-Pacific journey 
and was shown to be the most stable of all the viruses studied (83). SVA has been detected in 
feed ingredients and complete feed collected from two feed mills in Brazil, but further research 
will need to be performed to determine the risk of transmission through feed (84). In addition, 
environmental samples from an assembly yard in Canada have tested positive for SVA (85). The 
trafficking of animals to slaughter plants daily provides abundant opportunity for virus spread 
between slaughter plants and trucks and back to farms or collection points. Trucks have been 
shown to play a role in the spread of viruses as demonstrated by studies with porcine epidemic 
diarrhea virus (86, 87). Recently, risk factors for SVA positive pigs arriving at a slaughter plant 
included suppliers that raised pigs indoors and suppliers with multiple type sites (88).      
Semen positive for swine viruses, including CSFV, porcine respiratory and reproductive 
syndrome virus (PRRSV) and pseudorabies virus (PRV), has been experimentally shown to 
infect sows (89). Semen has tested PCR positive for SVA, but additional research will need to be 
performed to determine the potential for viral transmission during breeding (70). Muscle meat 
cuts were tested to understand if retail meat could be a risk of SVA transmission. Only 1.1% 
(2/190) were PCR positive for SVA, but both samples were virus isolation negative suggesting 
that retail meat is a low risk for SVA transmission (90). Little objective data has been collected 
regarding cull sow movements; but one study found a significant number of sows entered 
multiple collection points prior to reaching a slaughter facility and traveled on average over 240 
km from their site of origin, making the cull sow network a likely area of pathogen transmission 
(91). Samples from collection points in North Carolina from animals headed to slaughter tested 
positive for the presence of SVA by PCR suggesting that SVA does circulate in secondary and 
cull sow markets and mostly likely contributed to the spread of SVA nationally in the US (73).    
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Since the 2015 outbreaks reported in Brazil and the US, vesicular disease cases due to 
SVA have been found across the globe including China (92), Canada (85), Colombia (93), 
Thailand (94), and Vietnam (95). In March of 2015, SVA was discovered and isolated in China 
with farms reporting vesicular lesions in sows and acute death in neonates similar to Brazil (96).  
In October of 2015, sows transported to the US from Canada had vesicular lesions on arrival, 
which initiated a foreign animal disease (FAD) investigation. Tracebacks to the herd of origin 
detected SVA that was genetically similar to isolates found in China (85). In February of 2016, a 
breeding farm in Colombia broke with vesicular disease, and phylogenetic analysis of the SVA 
isolate clustered the Columbian strain with contemporary isolates from the US (98.5-98.9% 
nucleotide identity) rather than strains from Brazil (93). SVA was first detected in Thailand in 
October of 2016 with lesions in market-weight pigs. At a genomic level, this virus was most 
closely related (98.2%) to the first Canadian strain from 2011 (94). Research has suggested the 
SVA introduction to Thailand may not have been recent, but that the virus had evolved in the 
Thai swine population and remained undetected due to the presence of other pathogens that 
cause similar clinical disease, like FMDV (97). Finally, in January of 2018, a group of pigs from 
Vietnam diagnosed with FMDV also tested positive for SVA, and the sequence shared high 
homology with isolates collected from China in 2015 and 2016 (95). This case and others 
highlight the difficulties faced by countries with FMDV and SVA co-circulating in swine herds 
to understand virus spread and mount control responses to each virus.  
Brazilian isolates appear to have originated from a common source, since they are 
genetically similar and group together in a clade separate from most US isolates from the same 
time period (98). Similarly, isolates from the US also clustered together; and, in general, SVA 
isolates cluster according to geographic region (99). Surprisingly, early SVA isolates from China 
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(2015-2016) tended to cluster together near Canadian and Brazilian isolates, while isolates from 
2016-2017 began to cluster within the 2015 US isolates (100-105). Of note, one report 
commented that earlier isolates more closely related to Brazilian isolates caused acute death in 
neonates, while the more recent strains clustering with the US isolates did not cause clinical 
disease in piglets (106). Clusters of Chinese isolates spread throughout SVA phylogenetic trees 
with little relationship to area or year of isolation could imply multiple introductions into China 
and/or undetected circulation and adaptation in Chinese swine herds (107, 108).  The genetic 
distance of isolates between the US and Brazil was reported to be 2.71%, while the distance 
between the US and China isolates was 2.48% and 2.8% between Brazil and China isolates (99). 
The overall genetic divergence of contemporary isolates was 2.8%, but the genetic divergence 
between contemporary isolates (2011-2017) and historical isolates (1988-2010) was 6.32% (99). 
Another wave of outbreaks was reported in Brazil during the second half of 2018 in many of the 
same states that experienced outbreaks in 2015. Although the clinical disease presentation 
seemed more severe, phylogenetic analysis suggested the 2018 strains were not significantly 
different from those strains sequenced in 2015-2016 in Brazil (109).  
There have been multiple reports of recombination events with Chinese SVA strains. A 
few events involving Chinese isolates from 2017-2019 showed parental strains from 2015 US 
isolates (110, 111). In addition, a Chinese isolate from 2018 was reported to have SVV-001 as a 
parental strain, and an isolate from 2019 was reported to have the 2016 isolate from Colombia as 
a parental strain (112, 113). Finally, there have also been reports of recombination events with 
Chinese isolates from 2016-2019 involving two Chinese parental strains (111, 114). Thus, there 
is evidence of recombination of SVA in China dating back to at least 2016. These events have 
been found to occur across the SVA genome including events in P1, P2, and P3 (112). SVA’s 
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RdRP has been shown to play a central role in SVA replicative recombination, and mutation rate 
was linked to recombination rate (115). Though more research needs to done in this area with 
SVA, evidence of recombination events has been reported in many other picornaviruses, 
including FMDV, and can play a key role in virus evolution (116).  
Pathogenesis and Immune Response 
Vesicular lesions in swine can be found on the coronary bands, intradigital space, snout, 
lips, and tongue (117). Lesions can begin with erythematous areas or blanched areas of the skin 
progressing to vesicles with varying levels of fluid that rupture leaving an erosion on the skin 
that crusts over and resolves (72). Histologically, areas of separation between the dermis and 
epidermis with clefts are noted containing edema, fibrin, necrotic debris, and inflammatory 
infiltrates (neutrophils, lymphocytes, and plasma cells) (72, 118). Development of vesicular 
lesions on the coronary bands have been observed in as little as 48 hours in market-weight 
animals, but most animals develop vesicular lesions 3-6 days after experimental challenge and 
heal within 7-14 days (41, 71, 72, 119, 120). Snout lesion development has been described as 
delayed compared to the appearance of coronary band lesions and heals more quickly (119, 121). 
In addition, some studies have reported seeing less snout lesions compared to coronary band 
lesions (118, 122). Other clinical signs that have been reported intermittently in pigs inoculated 
with SVA include fever, lameness, lethargy, and decreased feed intake (26, 106).  
Although most experimental infection studies with contemporary SVA strains have 
resulted in most animals developing vesicular lesions, field reports have described varying levels 
of incidence (67, 70, 78, 123). It is still not understood why some animals develop vesicular 
lesions and others do not (124). Exposure dose may play a role considering most experimental 
studies with swine have used inoculum doses between 107 and 108 TCID50/mL, which may be 
higher than exposure levels in the field. Experiments with FMDV in swine have shown altered 
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infection dynamics and a shorter time to clinical signs with higher doses of inoculum (125, 126). 
There has also been speculation surrounding age-dependency of lesion development. One study, 
using a SVA isolate from China, inoculated pigs around 1, 2, and 3 months-of age. The oldest 
pigs were the only ones to develop vesicles on their coronary bands and snout, while the two 
groups of younger pigs did not develop any visible lesions (122). One hypothesis for differences 
in lesion development is density of the SVA receptor on susceptible cells in the epithelium of the 
coronary band and snout, which could be dependent on age or genetics of the pig (118). 
Viremia after experimental challenge lasts between 1-10 dpi with peak levels around 2-4 
dpi (41, 127, 128). Live virus has been isolated from serum on 2-3 dpi, but not later in infection 
(117, 128). Interestingly, it has been noted in recent experimental studies that not all challenged 
animals develop a viremia (120). Oral, nasal, and rectal swabs typically test PCR positive from 
1-21 dpi, but there are sporadic positive samples out an additional week or more with oral and 
nasal swabs often testing PCR positive longer than rectal swabs (118, 121). Virus isolation (VI) 
performed on swab samples was successful on samples most reliably during the first week after 
inoculation, which coincides with peak RNA levels measured by PCR; although much less 
frequent, VI positive oral and fecal swabs have occurred out to 21 dpi (72, 117, 120).  
Studies of SVA outbreaks in the field have supported observations from experimental 
studies. SVA shedding dynamics, during a natural infection at a sow farm over a 9 week period 
post onset of clinical signs, observed vesicular lesions for ~2 weeks and viremia for ~1 week, but 
rectal and tonsil swabs from both piglets and sows were PCR positive for SVA out 6 weeks post 
outbreak (123). Following an outbreak, a sow farm found rectal and tonsil swabs PCR positive 
on a breeding farm at least six weeks after the onset of clinical signs (79). For diagnostics in the 
field with unknown infection status, swabs may be a more reliable sample than serum due to the 
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greater longevity of SVA detection in swabs compared to serum. But, swabs of vesicular lesions 
are the best sample for the diagnosis of SVA, due to the high levels of virus compared to all 
other samples (119).   
The role of stress and its effect on SVA pathogenesis and disease manifestation have 
been of interest following the first reports of SVA in the US involving show pigs and finishing 
pigs being transported to market. Since experimental inoculation in the past had been 
unsuccessful, it was hypothesized that stress may be a required co-factor for clinical 
manifestation of SVA infection. This hypothesis was also supported by the fact that the virus had 
been found in healthy pigs without vesicular disease (73, 124). One early experimental 
inoculation with SVA treated half the pigs with an immunosuppressive regime of dexamethasone 
prior to challenge. Both groups developed vesicular lesions and had similar infection dynamics, 
although a greater percentage of dexamethasone treated pigs showed clinical signs 
approximately 24 hours earlier than those not treated (118). Similarly, animals that had 
transportation stress prior to challenge developed lesions slightly earlier than animals with no 
stressor prior to challenge, but viremia, shedding dynamics, and neutralizing antibody response 
were similar between both groups (121). Thus, these studies support stress is not required for 
lesion development, but it may accelerate development. 
There had also been speculation of stress causing SVA to recrudesce or to renew active 
replication. Recrudescence has been reported to occur in other viruses that infect swine including 
PRV, a herpesvirus that infects swine (129, 130). A field study observed an increase in the 
percentage of piglets positive for SVA in serum at weaning almost 3 weeks after the virus had 
been cleared from the serum of most piglets (123). An unconfirmed field report suggested that 
pigs without lesions present during marketing showed up to the slaughter plant ~12 hours later 
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with lesions. Lesions were not observed on other animals from the farm of origin leading to 
speculation of recrudescence. Experimental work to test this theory challenged three groups of 
pigs with SVA and 46 days after infection applied a stressor event: transport stress, 
dexamethasone treatment, or parturition. No lesions were observed after the stressor, but 
intermittent viremia and shedding was detected in all groups (121). Of note, shedding was still 
observed in some animals at the stressor event from the initial SVA challenge (121).   
The extended shedding seen in some animals infected with SVA could be attributed to 
persistence of the virus in tonsils. Live virus has been isolated from a tonsil 60 days after initial 
challenge, and in situ hybridization localized the virus to both tonsillar epithelial cells as well as 
lymphoid tissues (121). Double-stranded RNA (dsRNA) was detected by IFA in tonsils 
indicating a potential mechanism for persistence that has been shown for other viruses including 
PRRSV that can persist in the germinal centers of lymphoid tissues as dsRNA (131, 132). In 
addition, dsRNA is also a product of positive-sense RNA viral replication, so the dsRNA could 
also represent continued replication of SVA in the tonsillar tissue. Sows that farrowed ~46 days 
after initial exposure to SVA were able to transmit virus to their piglets supporting continued 
replication in animals long after the resolution of clinical signs (121). Although piglets were 
found positive for SVA, as with other experimental studies, the piglets did not demonstrate any 
clinical signs.  
Piglets in Brazil have been reported to have ulcerative lesions on the snout, tongue, and 
coronary bands in SVA affected farms; however, those lesions have not been reported frequently 
in piglets in the US (133, 134). Brazil also had more reports of neurologic disease in neonates, 
which was supported by immunolabeling of SVA found in the choroid plexus of the brain and 
the surrounding endothelium cells of blood vessels of piglets that died on SVA affected farms 
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(133). In addition, piglets submitted to a diagnostic lab in Brazil for ETNL had atrophic enteritis 
with positive immunolabeling in apical enterocytes as well as transmission electron microscopy 
evidence of viral particles similar in size and morphology to that of picornaviruses in the apical 
enterocytes (135). SVA was also detected in urinary epithelium by immunohistochemistry (IHC) 
with ballooning degeneration of the transitional epithelium (136). Histology and IHC 
demonstrated a multi-systemic infection of SVA in piglets; but quantification by PCR had 
demonstrated that the lymphoid organs have the highest levels of virus, which has also been 
observed in older swine after experimental challenge (118, 137). Lesions and virus in the urinary 
and enteric tracts suggest that urine and feces could be a mode of horizontal transmission of 
SVA. IHC detection of SVA in tissues from 1-2 day old piglets also suggests vertical 
transmission of the virus from sows (136).   
Due to the inability of early studies to reproduce clinical disease with experimental SVA 
challenge, it was hypothesized that older isolates were less pathogenic than contemporary SVA 
isolates (118). One study reported that pigs challenged with SVV-001 did not develop vesicular 
lesions but did replicate the virus and develop an antibody response; while the group challenged 
with a 2015 isolate developed clinical disease and had greater levels of SVA RNA in acute 
serum and swab samples, except fecal swabs (120). Both groups developed cross-neutralizing 
antibodies and cross-neutralizing T-cell responses suggesting conserved antigenic determinants 
(120). Another group compared the pathogenicity of two contemporary Chinese isolates (2016 vs 
2017) and found one isolate to be more pathogenic in pigs than the other, with the 2016 most 
closely related to Canadian isolates not causing vesicular disease in a group of finishing pigs 
(127). Recent cell culture work with 5 different Chinese isolates located in different SVA 
phylogenetic clusters also showed small differences in viral growth kinetics in ST cells (138). 
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Therefore, some SVA isolates have not caused vesicular disease in challenged pigs, and more 
research is necessary to correlate SVA genomic differences with pathogenic differences in SVA 
strains.  
Neutralizing antibody titers have been measured in pigs as early as 3-5 days after 
experimental infection, which has been correlated with VP2- and VP3-specific IgM responses 
(41, 72, 119, 128). This rise in neutralizing antibodies corresponds with the decline in viremia. 
IgG antibody response to infection follows IgM with titers beginning around 10 dpi (72, 118). 
VP2-specific IgG antibodies were detected longer than VP1 and VP3 (128). Neutralizing 
antibodies have been found in animals up to 5 months after initial exposure, but further research 
must be performed to determine the protective titer. CD4+ helper T cells, critical for antibody 
production, were detected by 7 dpi, while CD8+ and CD4+ CD8+ T cells (effector/memory) 
increased after 10 dpi (128). VP2-specific responses were highly suggestive that VP2 contains 
important B-cell and T-cell epitopes (128).   
Diagnostics 
PCR is an invaluable tool for virus detection and SVA diagnosis. SYBR Green and 
TaqMan-based real time RT-PCR assays have been developed with probes targeting different 
regions of the virus, including VP1 and 3D (139-141). In addition, a nested-PCR assay has been 
developed to amplify a fragment of VP1, which was able to identify SVA RNA in samples 
considered negative by RT-PCR (142). A real time RT loop-mediated isothermal amplification 
(real time RT-LAMP) assay was developed to provide a cheaper option for SVA detection (143). 
The RT-LAMP procedure has also been combined with a lateral flow dipstick for rapid 
visualization of results (144). Finally, a RNA RT-droplet digital PCR (RT-ddPCR) was 
developed that allows quantification without the need for standard curves and is resistant to 
inhibitors present in different sample types (145).  
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The ability to differentiate between viruses that cause vesicular disease in swine is 
important since they are clinically indistinguishable. This is especially significant for FMDV, 
since it is on the World Organization for Animal Health (OIE) list of notifiable diseases (146). 
To this end, a multiplex RT-qPCR assay was developed for quick differentiation of FMDV and 
SVA (74). Multiplex assays are particularly vital for those countries that have multiple endemic 
viruses that cause vesicular disease in swine, because the ability to track different viruses will be 
critical to understanding viral epidemiology to develop control and prevention plans. Of equal 
importance to differentiation is the speed at which the diagnosis can be made. In countries free of 
FMDV, there is a halt to swine movement when a vesicle is observed until FMDV has been ruled 
out. Pen side testing allows quicker results and could contribute to faster continuity of animal 
movements. To this end, a field-deployable RT-insulated isothermal PCR (RT-iiPCR) has been 
developed that can detect SVA in the field (147). Unfortunately, this test can rule in/out SVA, 
but it does not provide information about FMDV status.  
For countries with FMD negative status, identifying FMD would have severe economic 
ramifications including production loss, trade restrictions, control measures, and the cost of 
regaining FMD-free status (148). Due to the significant consequences involved with a FMDV 
positive diagnosis, testing for FMDV is highly regulated. In the United States, when a vesicle is 
observed in swine, a FAD investigation is instigated. Trained personnel collect a set of standard 
samples in duplicate to be sent to both the Foreign Animal Disease Diagnostic Lab (FADDL) 
and a National Animal Health Laboratory Network (NAHLN) lab to rule out FMDV. Therefore, 
even though pen side diagnostic tests for FMDV have been produced (RT-iiPCR and lateral flow 
device), governments may be reluctant to approve these platforms, due to ramifications of false 
positive/negative results (149-151). For example, a false negative result could lead to the 
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movement of positive animals and contribute to the spread of FMDV, which is considered one of 
the most highly contagious diseases of animals (152).    
Not only is it important to be able to detect the virus in swine via PCR, it is equally 
important to be able to measure the antibody response to infection. As opposed to PCR, serology 
can provide information on SVA exposure over time. SVA VP1 and VP2 recombinant protein 
indirect ELISAs have been developed by diagnostic labs to identify SVA antibodies in swine, 
which are more rapid and convenient for diagnostic labs versus assays that involve cell culture, 
like virus neutralization (VN) assays and indirect IFA (79, 153). One group found antibody 
responses to VP2 were higher than VP1 and VP3 and had higher binding affinity in the ELISA, 
which correlates with data that VP2-specific IgG antibodies were shown to last the longest in 
experimentally challenged pigs (128, 153). Indirect ELISAs can have high-cross reactivity, so a 
competitive ELISA has also been developed (42, 154). Although the scalability of ELISA assays 
are favored by diagnostic labs, VN and IFA assays are excellent confirmatory assays with high 
sensitivity and specificity and often used in research settings (72, 154). Recently, a eGFP-tagged 
recombinant SVA has been developed to facilitate reading VN assays (155). 
Both in situ hybridization (ISH) and IHC assays have been developed to detect SVA 
within tissues (134, 136). IHC assays detect viral antigen and require antibodies against the virus 
of interest, which in the case of SVA can be difficult to obtain commercially. In contrast, for 
RNAScope (ISH), a probe is ordered to a target genomic region of interest for virus detection in 
tissues (72, 134). Although it is rarely used for clinical diagnosis, electron microscopy has also 
been utilized to demonstrate particles with picornavirus morphology in animals infected with 
SVA (135).   
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Prevention/Control  
Disinfectants have shown differing levels of success at inactivating SVA on different 
surfaces at various temperatures. In one study, bleach (sodium hypochlorite) at a 1:20 dilution 
was most effective at inactivating the virus, with a quaternary ammonium disinfectant 
demonstrating intermediate success depending on surface and temperature, and a phenolic 
disinfectant performing the worst (156). Accelerated hydrogen peroxide at 1:20 for 10 minutes 
was also an effective disinfectant against SVA, as well as FMDV and SVDV (157). Ultraviolet-
C (UV-C, 254 nm wavelength) can also be used for an inactivation method, though it may be 
best suited as a redundant biosecurity measure because it was seen to be less effective with non-
enveloped viruses and required greater than 3,000 J/L for viral inactivation of SVA (158).  
Trypsin was suspected to be the source of contamination when SVA was discovered as a 
cell culture contaminant, due to evidence of swine being the natural host for SVA and since 
porcine trypsin is used commonly in cell culture work. Some swine vaccines are grown in cell 
culture, thus raising concern for SVA contamination during the vaccine manufacturing process. 
Vaccine distribution nationally and around the globe could serve as a route for the dissemination 
of SVA. Two lots of trypsin that had received 25-40 kGy of gamma-irradiation tested PCR 
positive and also virus isolation positive indicating live virus (159). Of note, after the trypsin 
samples received a second round of gamma-irradiation, SVA was inactivated. Thus, animal 
biologic manufacturers using porcine trypsin should add SVA to their exogenous agent testing to 
ensure that SVA is not inadvertently being spread through swine biologics.   
Multiple vaccine platforms have been evaluated for efficacy against SVA challenge. A 
whole-virus inactivated vaccine made from a Chinese SVA isolate mixed with an adjuvant given 
in one dose provided protection against homologous challenge by preventing the development of 
clinical signs and viremia (160). Also, a recombinant SVA strain used as a live attenuated 
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vaccine given in a single dose induced a robust antibody response; and after challenge with SVA, 
animals did not develop any clinical disease, had reduced viremia, and had reduced viral 
shedding compared to non-vaccinated animals (161). Interestingly, an inactivated vaccine tested 
in the same study did not produce detectable neutralizing antibodies until after a second dose was 
given; and after challenge, the inactivated SVA vaccine did not protect against the development 
of vesicular disease (161). Inactivated virus vaccines do not contain live virus, so they are safer 
than a live attenuated virus vaccine that replicates and could revert to a virulent form. On the 
other hand, since live attenuated viruses replicate in the animal, they may generate a more robust 
humoral and cell mediated immune response than inactivated vaccines.  
Recently, a virus-like particles (VLPs) vaccine for SVA has been tested in swine against 
SVA challenge. VLPs consist of viral structural proteins that spontaneously self-assemble into 
particles antigenically indistinguishable from the native virus (162). An advantage of VLPs is 
they present viral antigens in a more authentic conformation compared to typical subunit 
vaccines with recombinant proteins (163). Pigs vaccinated with SVA VLPs and challenged with 
a 2017 Chinese isolate did not develop clinical disease or viremia. This study also showed 
similar efficacy of a one-dose inactivated virus vaccine. Having an effective commercial vaccine 
for SVA could reduce the occurrence of SVA-related vesicular disease, thus reducing the 
economic burden of FADIs in FMD-free countries and viral load of SVA in endemic regions.  
Swine Vesicular Diseases 
There are currently five known viruses that cause clinically similar vesicular disease in 
swine: FMDV, SVDV, vesicular stomatitis virus (VSV), vesicular exanthema of swine virus 
(VESV), and SVA. Table 1 compares the etiology, epidemiology, and pathogenesis of these 
viruses. In addition to viruses, there has been a report of vesicular disease in white pigs due to 
ingestion of phototoxic compounds from celery and parsnips and cases of IVD where no 
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causative agent can be determined (164, 165). Since vesicular lesions appear clinically identical, 
diagnostics must be performed to determine the causative agent or rule out known causes. There 
is a multiplex PCR assay that can simultaneously detect VSV, SVDV, and FMDV (166). With 
the emergence of SVA, new multiplex assays will need to be developed (74). Depending on the 
status for each of the viruses in a country, one or more of these viruses can be reportable either 
nationally or internationally to the OIE.  
FMDV is a OIE notifiable disease and can have severe consequences for the agriculture 
industry, international trade, and the economy. FMDV infects swine, but also other cloven-
hoofed animals including cattle, sheep, goats, and wildlife (152). The FMDV outbreak in the 
United Kingdom in 2002 was estimated to cost around 10 billion dollars (167). Not only can it be 
economically devastating for FMDV-free countries experiencing an outbreak, but also for those 
countries where FMDV is endemic with estimates of production losses and vaccination costs 
between 6.5 and 21 billion dollars (168). FMDV is currently endemic in many countries in Asia, 
Africa, and the Middle East (169). It is critical to investigate any vesicular lesions in swine 
outside of these countries to rule out the presence of FMDV. FMDV is considered one of the 
most contagious diseases of livestock, so any delay in identification of the virus could lead to 
greater spread of the virus in a naïve population (170).  
There are two distinct serotypes of VSV, Indiana (VSIV) and New Jersey (VSNJ) with 
VSNJ being responsible for most cases reported in the Americas (171). In experimental studies 
with swine VSNJ isolates were more virulent than VSIV (172). Outbreaks in livestock, mostly 
equines, in the US typically occur every 8-10 years in the west, but recently they have been 
occurring more frequently (173). The last reported incident of VS in swine in the US was 1968 
(174). Virus has been isolated from biting and non-biting insects and they are believed to play a 
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major role in mechanical transmission (175). In addition, VSV is zoonotic and humans that have 
had contact with the virus have been infected (176). 
SVDV has been considered endemic in Southern Italy and occasional outbreaks have 
occurred in other regions in Eastern and Western Europe and Asia (177, 178). As with SVA, 
subclinical infections of SVDV can be common (179). SVDV is very resistant to environmental 
factors such as freezing and dehydration, as well as common disinfectants (180). Interestingly, 
SVDV evolved from the human coxsackie B virus serotype 5 to make the species jump from 
humans to swine (181). Pigs challenged with coxsackie B virus did not develop clinical disease 
but did have a transient neutralizing response (182). SVDV along with VSV used to be OIE List 
A notifiable diseases but were de-listed in 2014 (183). 
VESV was first discovered in 1932 in California and sporadic cases were recognized in 
swine fed raw garbage (184). In 1952 the virus spread to swine producing regions outside of 
California and was eradicated in 1959, which was thought to be associated with the enforcement 
of laws to prevent the feeding of garbage to swine (185). In 1972, San Miguel sea lion virus 
(SMSV) was isolated from California sea lions that developed fluid filled vesicles on non-haired 
portions of the flippers and is indistinguishable from VESV (186, 187). SMSV strains have 
subsequently been isolated from other marine mammals, fish, and flukes (188). Swine inoculated 
with various serotypes of SMSV have developed vesicular disease (189, 190). 
As SVA spreads around the globe it will continue to present challenges due to its clinical 
similarity with FMDV. Improving knowledge about the epidemiology, viral evolution, and 
pathogenesis of SVA may help focus efforts directed at controlling the spread of SVA and future 
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Abstract 
Background: Senecavirus A, commonly known as Seneca Valley virus (SVV), is a 
picornavirus that has been infrequently associated with porcine idiopathic vesicular disease 
(PIVD). In late 2014 there were multiple PIVD outbreaks in several states in Brazil and samples 
from those cases tested positive for SVV. Beginning in July of 2015, multiple cases of PIVD 
were reported in the United States in which a genetically similar SVV was also detected. These 
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events suggested SVV could induce vesicular disease, which was recently demonstrated with 
contemporary US isolates that produced mild disease in pigs. It was hypothesized that stressful 
conditions may exacerbate the expression of clinical disease and the following experiment was 
performed. Two groups of 9-week-old pigs were given an intranasal SVV challenge with one 
group receiving an immunosuppressive dose of dexamethasone prior to challenge. After 
challenge animals were observed for the development of clinical signs and serum and swabs 
were collected to study viral shedding and antibody production. In addition, pigs were 
euthanized 2, 4, 6, 8, and 12 days post inoculation (dpi) to demonstrate tissue distribution of 
virus during acute infection. 
Results: Vesicular disease was experimentally induced in both groups with the duration 
and magnitude of clinical signs similar between groups. During acute infection [0-14 days post 
infection (dpi)], SVV was detected by PCR in serum, nasal swabs, rectal swabs, various tissues, 
and in swabs from ruptured vesicles. From 15 to 30 dpi, virus was less consistently detected in 
nasal and rectal swabs, and absent from most serum samples. Virus neutralizing antibody was 
detected by 5 dpi and lasted until the end of the study. 
Conclusion: Treatment with an immunosuppressive dose of dexamethasone did not 
drastically alter the clinical disease course of SVV in experimentally infected nursery aged 
swine. A greater understanding of SVV pathogenesis and factors that could exacerbate disease 
can help the swine industry with control and prevention strategies directed against this virus. 
   
Background 
Vesicular disease in swine is recognized by the development of vesicles on the feet, 
snout, and less frequently in the oral cavity (1, 2). Nonspecific signs include fever, lethargy, 
anorexia, and lameness. Known viral causes of swine vesicular disease are vesicular stomatitis 
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virus, swine vesicular disease virus, vesicular exanthema of swine virus, and importantly, foot-
and-mouth disease virus (FMDV). FMDV causes one of the most highly contagious diseases of 
livestock that can result in devastating economic losses to the agricultural industry and disruption 
of the human food supply (3, 4). Since vesicular diseases of swine are indistinguishable in the 
field, each case must be treated as if it was an FMDV infection, which triggers a significant 
response in countries where FMDV is not endemic. Although rare, swine vesicular diseases have 
occurred in countries without known vesicular viruses or the known causes have been ruled out, 
resulting in the diagnosis of porcine idiopathic vesicular disease (PIVD). 
Senecavirus A, commonly known as Seneca Valley virus (SVV), is a non-enveloped, 
single-stranded RNA virus in the family Picornaviridae first identified as a tissue culture 
contaminant in 2002 (5).  A retrospective analysis confirmed that since the late 1980s, SVV has 
been sporadically isolated from swine samples in the United States (US) (6), and detected by 
PCR in more recent cases of PIVD (7, 8).  Although early attempts to induce vesicular disease 
with field SVV isolates were unsuccessful (6, 9-11), it was presumed that SVV was the causative 
agent. 
In late 2014, outbreaks of vesicular disease in finishing swine, and in sow farms with 
concurrent reports of increased neonatal mortality occurred in multiple states in Brazil (12, 13). 
As part of the diagnostic investigations ruling out known causes of vesicular disease in swine, 
SVV was identified by PCR and virus isolation in multiple samples from affected animals. In 
July 2015, similar outbreaks began in the US and SVV was also detected in those cases (14-17). 
Collectively, the association of SVV with vesicular disease in Brazil and the US provided strong 
support for SVV as the causal agent. This was confirmed with the fulfillment of Koch’s 
postulates in 9-week old pigs using a 2015 SVV isolate from the US (18). Since that report, 
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vesicular disease was also experimentally reproduced with SVV infection in nursery pigs (19) as 
well as in finishing-aged swine (20). Although SVV was rarely detected in North America prior 
to the 2014/2015 unprecedented emergence of PIVD in Brazil and the United States, it has been 
detected many times since then in the respective countries as well as recent novel case reports in 
Canada (21), China (22-24), Thailand (25), and Colombia (26). Interestingly, viruses from these 
recent outbreaks are genetically similar sharing > 94% nucleotide identity at the full-length 
genomic level.  
In an early PIVD report there was speculation that stressful events in the field may 
predispose pigs to SVV clinical disease; e.g., after transportation to slaughter (8).  Similar 
observations in the 2014/2015 SVV cases supported this assumption which led to the original 
experiment using an immunosuppressive model to test the hypothesis that administration of a 
synthetic glucocorticoid would exacerbate the SVV infection in swine. Surprisingly, both non-
dexamethasone treated pigs as well as dexamethasone treated pigs developed vesicular disease of 
comparable severity. The acute phase of the vesicular disease in the non-dexamethasone SVV-
challenged pigs was previously reported (18). This manuscript describes the kinetics of the SVV 
infection and the comparison between the dexamethasone and non-dexamethasone treated pigs. 
 
Results 
Clinical and microscopic observations 
All pigs were free from signs of vesicular disease prior to challenge, and all control pigs 
appeared normal throughout the experiment. One pig in the Dex-SVV group became anorexic at 
2 dpi and was removed from the experiment because it was not competitive in a group 
environment. The pig’s health continued to deteriorate, and it died 2 days post removal from the 
group. Although no definitive cause of death was determined, it is believed SVV did not 
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contribute to the illness and death since the only clinical signs recognized in the other pigs was 
transient lameness.   
A mild transient lameness was recognized in 2-3 pigs from both the Dex-SVV and SVV 
groups on 2 and 3 dpi. No gross abnormalities in behavior or appearance were observed in pigs 
euthanized on 2, 4, 8, and 12 dpi for necropsy. 
The acute lesions for the SVV pigs were previously described (18). The lesions that 
developed in the Dex-SVV group were indistinguishable from the SVV group and are briefly 
described below. At the 4 dpi daily observation, cutaneous lesions were detected in 8/11 Dex-
SVV pigs (72.7%) and 7/16 SVV pigs (43.8%). Cutaneous lesions consisted of small vesicles 
(about 3mm x 3mm) and/or erosions first noticed at 4 dpi in the interdigital spaces and coronary 
bands of one or more feet. At 5 dpi, all Dex-SVV pigs were observed with vesicular lesions and 
14/15 SVV pigs had at least one lesion. Lesions were recognized as small, pale or blanched areas 
of swelling on the coronary band that would grow in size, thicken and become raised (Figure 1). 
Usually, the skin would wear away leaving an erosion or ulcer that could coalesce with adjacent 
lesions. Snout lesions, when present, were mostly recognized as an elliptical erosion (3mm x 
5mm) that was on the dorsal ridge of the snout which quickly healed. No new coronary band 
lesions were recognized after 6 dpi at which time the lesions began to heal. 
 
Figure 3.1: Vesicular lesions from 9-week-old swine. A) Ruptured vesicle in the interdigital space. B) 
Intact vesicle on the lateral coronary band.  
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Microscopic examination of coronary band tissue sections from the pigs euthanized 
revealed lesions in the 4 and 6 dpi pigs. Extensive areas of epidermis, predominantly stratum 
spinosum, was affected and effaced by multifocal to coalescing vesicles, containing fibrin, 
edema, necrotic debris and infiltration of lymphocytes and plasma cells (Figure 2). Occasionally, 
these vesicles progressed to pustules, which were characterized by degenerate neutrophils 
admixed with variable amounts of fibrin, cellular and karyorrhectic debris. A few of these 
inflammatory cells were multifocally observed in the superficial dermis (beneath the affected 
epidermis).  
 
Figure 3.2: Microscopic lesions from the coronary band. Cut section of the epidermis with the (A) 
stratum corneum and (B) stratum spinosum. Red arrows point to an oval shaped vesicle disrupting the 
stratum spinosum, which contains small numbers of neutrophils, lymphocytes, varying amounts of fibrin, 
edema admixed with necrotic and cellular debris.  
SVV RNA detection 
Selected samples from control animals all tested negative for SVV RNA by PCR.  In 
serum samples of both Dex-SVV (n=11) and SVV (n=12) groups SVV RNA was detected in 
pigs as early as 1 dpi (Figure 3). For the Dex-SVV group, peak viremia occurred at 5 dpi with a 
mean value of 5.7 x104 genomic copies per microliter (GC/µL) of serum. Peak of viremia was 
observed at 3 dpi in the SVV group with a mean value of 3.1 x105 GC/µL of serum. Though 
different peaks were observed, no statistically significant differences were detected in the 
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magnitude of viremia between Dex-SVV and SVV groups. Mean SVV RNA concentration in 
serum in both groups decreased over time with minimal amounts detected at 15 (0.6 GC/µL) and 
22 dpi (0.3 GC/µL). 
In nasal swabs, SVV RNA was detected in one or more pigs at all time-points of the 
study, with a peak mean value of 2.0 x105 GC/µL in the Dex-SVV group and 8.8 x104 GC/µL in 
the SVV group at 3 dpi (Figure 3). By 30 dpi, GCs were found at low levels in all animals of the 
SVV group and only three animals were PCR positive in the Dex-SVV group. There was no 
statistically significant difference in GC/µL levels between the Dex-SVV and SVV group.  
In rectal swabs, SVV RNA levels were approximately 2 to 3 logs lower than those in 
nasal swabs (Figure 3). An observable peak occurred at 3 dpi for the Dex-SVV group (9.5 x102 
GC/µL) and at 5 dpi for the SVV group (2.6 x102 GC/µL) with statistically significant 
differences between the two groups detected at 3 and 5 dpi (p < 0.05). In addition, both 
experimental groups had a transient increase in SVV RNA levels from 11 dpi to 15 dpi.  
 
Figure 3.3: SVV infection dynamics. Virus shedding in nasal and rectal swabs and viremia levels 
detected by RT-qPCR. Quantity of viral RNA is expressed as genomic copies per microliter. Error bars 
represent the standard error of the mean. Red data lines represent the Dex-SVV group and black data lines 
represent the SVV group. Nasal swabs are designated with a circle, rectal swabs with a square, and serum 
with triangles. No viral shedding or viremia was detected in control animals.  
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 SVV RNA was detected in almost every tissue tested in each pig necropsied at 2, 4, 6, 8, 
and 12 dpi (Figure 4). In general, the lowest RNA levels were detected in pig 234 (2 dpi) with 
peak RNA levels detected in pig 235 (4pi) followed by a reduction over time for pigs 236 (6 
dpi), 237 (8 dpi), and 238 (12 dpi), respectively. SVV RNA was found at much higher 
concentrations in the tonsil (7.83 x105 GC/µL at 4 dpi) and inguinal lymph nodes (6.55 x105 
GC/µL at 6 dpi) compared to the other tissues.  
  
Figure 3.4: Tissue distribution of SVV. Viral load present in selected tissues from necropsied pigs on 2, 
4, 6, 8, and 12 dpi respectively. Quantity of viral RNA was determined by RT-qPCR and expressed as 
genomic copies per 20 mg of tissue.  
Serological responses 
All 0 dpi sera samples were negative for antibodies against SVV by IFA and VN assays. 
All challenged pigs developed IgG IFA antibodies against SVV by 11 dpi with titers ranging 
from 1:320 to 1:640. Pigs from both groups had a similar IgG response throughout the study with 
most having a titer of 1:1280 on 30 dpi (Figure 5). All but 2 pigs in the Dex-SVV group 
developed measurable neutralizing antibodies by 5 dpi. VN titers peaked in both groups at 7 dpi. 
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Again, the neutralizing antibody response was similar for both the Dex-SVV and SVV groups 
over the course of the experiment as shown in Figure 5. Control pig sera had VN titers ≤ 1:4. 
  
Figure 3.5: Antibody response to SVV infection. Indirect immunofluorescence assay measured IgG 
antibody response to SVV infection. Virus neutralization assay measured neutralizing antibody response 
to SVV. Red data lines represent the Dex-SVV group and black data lines represent the SVV group. IFA 
titers are depicted with circles while VN titers are designated with triangles. Error bars represent the 
standard error of the mean. 
 
Discussion 
Our hypothesis for this study was that stress induced through an immunosuppressive dose 
of dexamethasone would exacerbate clinical disease in SVV challenged pigs compared to those 
not treated with dexamethasone. This experimental question was derived from failed attempts 
prior to 2016 to reproduce vesicular disease with SVV, and the observations that PIVD cases 
were associated with times of stress such as transportation of finishing pigs to market (8) and 
congregations of show pigs. In this study, SVV infection induced prolific vesicular lesions in 
both the SVV and Dex-SVV treatment groups. The onset, character, and duration of the lesions 
were similar between groups indicating the dexamethasone treatment did not dramatically alter 
the clinical disease of pigs after SVV challenge. More pigs developed vesicular lesions earlier in 
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the Dex-SVV group, but by 5 dpi all but one pig in this experiment developed clinical signs. For 
the purposes of this discussion, both groups will be discussed as one unless noted otherwise.  
Development of vesicular disease in both challenge groups was surprising since 
experimental infections reported before 2016 were unable to induce clinical disease (6, 9-11).  
Vesicular disease reproduced in this study was compatible with early field reports of SVV-
related PIVD in finishing-aged pigs and sows (12, 13, 17), and similar to recent reports of 
experimentally induced vesicular lesions with US wild-type virus in 3-week-old pigs (19) and 55 
kg pigs (20). Collectively, this research may provide insight into the kinetics of SVV-associated 
vesicular disease that can provide an evidence for recommendations for diagnostic sampling and 
possible control strategies.  
In this study, lesions were first noted in the interdigital spaces when pigs were observed 
at 4 dpi. It is likely the onset of foot lesions began at an earlier time-point, given that by 4 dpi 
some pigs already had both intact and ruptured vesicles on their feet. The incidence of foot 
lesions peaked about 5-6 dpi and most lesions had resolved in about a week after onset of clinical 
signs. Our timeline of vesicular lesion development is similar to that reported by Joshi et al. in 
finishing pigs experimentally inoculated with SVV where lesions were first observed at 4 dpi 
(20). In contrast to onset and incidence of coronary band lesions, snout lesions observed in this 
study were first recognized around 7 dpi in just a few pigs as one or two small elliptical plaques 
on the dorsal ridge of the snout. In comparison, a higher incidence of snout lesions was reported 
in older (20) and nursery age pigs (19).  
Viremia and viral shedding were measured by RT-PCR to gain a better understanding of 
SVV infection kinetics. PCR results revealed a rapid onset of viremia with many pigs testing 
positive for SVV in serum by 1 dpi. Peak RNA concentration in sera occurred at 3-5 dpi 
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followed by a rapid decrease becoming almost undetectable by 15 dpi. Viral shedding also had a 
rapid onset with both nasal and fecal swabs testing positive for SVV at 1 dpi. The Dex-SVV 
group had statistically higher levels of SVV detected by PCR at 3 and 5 dpi in the rectal swabs. 
Virus was detected longer in nasal swabs than fecal swabs, especially in the SVV group. By 30 
dpi most pigs in either group were SVV-negative on rectal swab, but some of the SVV group 
were still nasal swab positive for viral RNA, though there was no statistical difference between 
groups. A similar shedding pattern was observed by Joshi et al. who reported that oral, nasal, and 
fecal swabs became PCR negative by 28 dpi in finishing pigs (20). Oral swabs were not collected 
in the present study, but others have reported a greater amount of virus detected and longer 
shedding compared to fecal or nasal swabs (19, 20).  
In the pigs euthanized from 2 – 12 dpi, 4 dpi was the time point with highest detection of 
SVV nucleic acids in tissues. In general, the tissues with the greatest SVV RNA presence were 
coronary band epithelia, tonsils, inguinal and mesenteric lymph nodes, lung, liver, and spleen. In 
addition, most tissues had higher SVV RNA concentrations than serum, which suggests that viral 
concentrations in the tissues is not solely due to blood contamination. A similar tissue 
distribution was reported in mid-finishing swine during acute infection in addition to lymph 
nodes, spleen, intestine, kidneys, and tonsils testing positive by PCR 38 days after challenge 
(20). Similarly, diagnostic investigations conducted in sow herds affected by vesicular disease 
and neonatal mortality in the US and in Brazil described detection of SVV nucleic acids in most 
tissues of piglets including the small intestine, tonsil, lung, heart, liver, spleen, kidney, 
myocardium and cerebellum (27, 28). Previous field case reports have documented detection of 
SVV in scrapings of ruptured vesicles and ulcerative lesions by PCR in sows and finishing pigs 
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(7, 12, 13, 28). Based on PCR results in our study, vesicular fluid/swabs had the highest 
concentration of virus compared to other samples. 
The onset of the humoral immune response was similar for both groups with antibody 
titers first being detected at 5 dpi by VN assay and 11 dpi by IFA assay. The onset and peak of 
antibody titers was more rapid for neutralizing antibody response compared to IgG measured by 
IFA assay. Similarly, Joshi et al. detected VN antibody as early as 5 dpi, which was also 
described by Yang et al., and SVV-specific IgG antibodies by 10 dpi (11, 20). Chen et al. 
reported neutralizing antibody response as early as 3 dpi in weaned pigs (19). Aforementioned 
studies have credited the early neutralizing antibody response for the quick decline in viremia 
reported in various aged swine. The duration of a SVV humoral immune response is unknown 
though unpublished work has demonstrated sterilizing immunity in gilts challenged five months 
after initial exposure to wild type SVV (Buckley et al., unpublished). 
Seneca Valley virus is in the same virus family as FMDV and shares many structural 
characteristics as well as a similar clinical presentation. Vesicular lesions can develop within 24-
48 hours of FMDV challenge (2, 3, 29), and are most commonly found on the coronary bands 
(30). FMDV can also be detected in serum as soon as 24 hours after exposure followed by 
gradual decline over a couple of weeks (31).  Antibodies against FMDV have been detected by 
ELISA around 7 dpi (IgM) and 14 dpi (IgG, IgA) in swine either inoculated or in direct contact 
(32). Although vesicular lesions contain the highest concentration of FMDV, virus replication 
does occur in other tissues, e.g., in the tonsil (31). This study and others have consistently found 
high concentrations of SVV nucleic acids present in the tonsil not only acutely, but also in 
convalescent swine (15, 20), which may provide evidence for the tonsil being a primary site of 
viral replication. The kinetics of the SVV infection are similar to FMDV; however, it is unknown 
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if SVV is as infectious as FMDV. Replication and shedding of SVV from the tonsil into the 
oropharyngeal cavity probably plays an important role in producing SVV-positive oral 
secretions, and may contribute to contamination of the nasal passages and the finding of SVV-
positive nasal swabs. However, the possible replication of SVV in nasal mucosa has not been 
ruled out.  
Unpublished observations from our laboratory support recent field reports describing 
environmental contamination with SVV nucleic acid (33), which combined with normal pig 
behavior such as rooting and inquisitive chewing, could cause false-positives in oral fluid 
samples. The extended presence of SVV in tonsil tissue may help explain the apparent longer 
shedding patterns reported for oral fluids and nasal swabs when compared to fecal swabs (19, 
20). Further study will be required under experimental conditions to characterize the duration of 
shedding of infectious virus from the oral cavity.  
Results from Chen et al., Joshi et al., and the present study can certainly be used for 
diagnostic recommendations for nursery to mid-finishing pigs that will be presented 
dogmatically for simplicity. Viral RNA can be detected in serum from at least 2-7 days, in feces 
(rectal swabs) from at least 2-15 days, in nasal swabs from at least 2-15 days, and in oral fluids 
from at least 2-21 days post infection. During the acute infection viral RNA can be detected in 
many tissues for at least 2-12 days post infection and can also serve as potential diagnostic 
samples. Finally, swabs of vesicular lesions may serve as the best sample to collect during 
clinical disease to reliably detect the presence of SVV due to the large quantities of virus found 
in that location. Lastly, it is expected that sows infected with SVV will have similar infection 
kinetics to nursery and mid-finishing swine and sample recommendation listed above would also 
pertain to mature animals. 
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Compared to other species, swine are relatively resistant to glucocorticoids (34, 35); 
however, their use has induced recrudescence of latent pseudorabies virus in swine indicating 
glucocorticoids can alter or suppress a pig’s immune system (36). Dexamethasone administration 
in this study was based on previous studies that successfully induced recrudescence of wild-type 
and attenuated PRV vaccine (36), and presumably this dosing schedule would be a substitute for 
stress that would alter the immune system allowing for enhanced vesicular disease. The Dex-
SVV group had more pigs observed with vesicular lesions on 4 dpi, but by 5 dpi all except 1 pig 
was effected in both groups. In addition, there were higher concentrations of SVV detected in 
rectal swabs on 3 and 5 dpi compared to the SVV group. It is unknown if a higher glucocorticoid 
dose might have altered the disease course more significantly, but such efforts may not be 
needed with contemporary SVV isolates based on this experiment and the previous successful 
reports (19, 20) 
The relative ease in which vesicular disease was produced in both groups of pigs in this 
study, and in the experiments of Chen et al. and Joshi, et al. provides a basis for a variety of 
questions and assumptions about contemporary SVV isolates, and why attempts to reproduce 
vesicular disease prior to 2016 were unsuccessful. First, the genetic similarity of current SVV 
isolates from Brazil, U.S., Canada, China, Thailand, and Colombia suggests a recent common 
ancestor which might explain the timing of newly recognized outbreaks across separate 
continents. Second, there may be a mutation in SVV that increased the likelihood that 
contemporary viruses are more likely to induce vesicular disease than viruses isolated before 
2014. If either of these factors played a role in the emergence of the mini SVV epidemics, then 
there must be some explanation for the relatively recent distribution of the common virus among 
continents. However, an increased awareness of potential SVV-related vesicular disease may be 
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contributing to the current observations. For example, the increase in reports of clinical disease 
associated with SVV isolates in China (24) and Thailand (25) that are more distantly related 
genetically to the contemporary Brazilian and US isolates suggests current clinical cases are not 
completely dependent on the emergence of a new lineage of virus. Third, there may be a novel 
cofactor(s) such as another infectious agent allowing disease to develop, which if true, must also 
have been transmitted to different continents. Fourth, there may be a genetic predisposition to 
clinical disease that is more prevalent now when compared to pre-2014 swine, and this trait has 
been slowly building in swine herds in countries reporting recent events. In addition, there may 
be an age-dependent effect on clinical presentation of disease which makes it more difficult to 
observe disease in young pigs compared to mature swine. The focal nature of vesicular disease 
demonstrates a discrete viral tropism for a cell type in a specific anatomical site, i.e., coronary 
band tissue. Such a condition might involve an increased density of this cell type in older swine, 
or this tissue may be more prevalent in one genetic line compared to another which would 
contribute to the presence of gross lesions. Lastly, there is the possibility that two or more of the 
above factors contributed to the emergence of the mini SVV epidemics.  
 
Conclusions 
This study adds to the growing body of knowledge about the pathogenesis of SVV in 
swine that has focused on understanding the acute infection (clinical disease, viremia, viral 
shedding, virus distribution in tissues, and immune response). This work has demonstrated the 
need to investigate the duration of immunity in convalescent swine and the spectrum of 
immunity against historical and contemporary strains to discern why an apparent change has 
occurred in the ecology of SVV in swine. The clinical description and kinetics from this study 
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can also help diagnosticians and veterinarians improve strategies to control this disease and 
differentiate it from other vesicular diseases in swine.  
 
Methods 
Cells and virus 
A swine testicular (ST) cell line (ATCC® CRL-1746; American Type Culture Collection, 
Manassas, VA) was cultured at 37 °C and 5% CO2 in minimum essential medium (MEM, 
MilliporeSigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS, AtlantaBio, 
Flowery Way, GA), 1x gentamicin, and 1x glutamax (Life Technologies, Carlsbad, CA). NCI-
H1299 cells (ATCC® CRL-5803) were cultured under the same conditions in Dulbecco’s 
modified Eagle’s medium (DMEM, MilliporeSigma) supplemented with 10% FBS (AtlantaBio).    
SVA15-41901SD was isolated on ST cells from samples collected from a barn of 
finishing pigs in South Dakota that developed vesicular lesions during the summer of 2015 (15). 
The second and third passage of the virus were combined to create a larger volume of working 
stock virus which was utilized for inoculum and laboratory assays. The stock virus had a titer of 
4.75 x 107 plaque-forming units (PFU)/ml and was tested for purity by next-generation-
sequencing that only detected SVA. 
Animals and experimental design 
Forty-nine conventionally-raised weaned pigs were purchased, randomly assigned ear 
tags and housed at the USDA-ARS-NADC campus in accordance with Institutional Animal Care 
and Use Committee guidelines (ACUP #2867) until 9 weeks-of-age at which time 29 pigs 
received SVV at a dose of 4.75x107 PFU/animal via intranasal inoculation. A LMA® MAD 
Nasal™ Intranasal Mucosal Atomization Device (Teleflex; Morrisville, NC) was used for 
delivery of about 2.5 mL of the atomized inoculum into each nostril for a total of 5 mL. Twelve 
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pigs (Dex-SVV group) based on sequential ear tag numbers were given an immunosuppressive 
treatment of dexamethasone (AgriLabs; St. Joseph, MO) intramuscularly in the neck for 5 days 
prior to challenge as follows: day 1, 2.3 mg/kg of body weight twice a day (BID); days 2-5, 1.1 
mg/kg BID. Seventeen pigs (SVV group) did not receive any treatment before challenge. The 
remaining 20 pigs were unchallenged control pigs (Control group). Each group was housed in a 
separate animal-biosafety-level 2 room, with at least 17 square feet/pig and constant access to 
feed and water. One pig each from the SVV group was euthanized on 2, 4, 6, 8, and 12 days post 
inoculation (dpi). At the time of euthanasia, the animal was physically restrained for the 
intravenous administration of a barbiturate (Fatal Plus, Vortech Pharmaceuticals, Dearborn, MI) 
following the manufacturer label dose (1 mL/4.54 kg). At the conclusion of the study the 
remaining pigs were also euthanized in the same manner.  
Sample collection  
Progression of clinical disease for each pig was assessed by daily observations for 
lameness and vesicular lesions. Antemortem sampling consisted of collection of whole blood in 
serum separation tubes (BD Vacutainer®, Franklin Lakes, NJ), and nasal and rectal swabs. 
Swabs (Puritan Medical Products, Guilford, ME) were collected and immersed in 3 ml of serum-
free MEM (MilliporeSigma).  Samples were collected on 0, 1, 3, 5, 7, 11, 15, 23, and 30 dpi 
from the SVV and Dex-SVV groups.  Pigs from the control group were sampled at 0, 7, 15, and 
29 dpi. When vesicles were observed, vesicular fluid collection was attempted via aspiration or 
swabs. Blood tubes were centrifuged to harvest the serum. Sera, vesicular fluids, and swab tubes 
were stored at -80 °C until time of testing.  
In the pigs euthanized on 2, 4, 6, 8, and 12 dpi, all postmortem examinations were 
performed immediately after euthanasia, and tissue specimens collected included snout and 
coronary band epithelium, tonsil, lymph nodes (retropharyngeal, mesenteric, and/or inguinal), 
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lungs, heart, liver, spleen, kidney, small and large intestine, brain and spinal cord. For each 
anatomically defined specimen, one approximate 10 g of tissue was collected and placed into a 
self-sealing plastic bag on dry ice for transfer within 2 hours to a -80 °C freezer. Tissues were 
thawed and 20 mg of each sample resuspended in 5 mL 1x PBS (Thermo Scientific, Waltham, 
MA) in individual gentleMACS™ M tubes (Miltenyi Biotec, Auburn, CA). Tissue was 
dissociated using a gentleMACS™ Octo-Dissociator (Miltenyi Biotec, Germany) following the 
manufacturer’s recommendations. After dissociation, tissue suspensions were aliquoted in 2 mL 
cryogenic vials (Corning, Corning, NY) and frozen at -80 °C until time of processing. For 
histology, skin sections from the coronary band region were collected in 10% neutral buffered 
formalin. Sections were fixed in formalin for 24 hours, routinely processed, paraffin-embedded, 
sectioned at 4-μm thickness, and stained with hematoxylin and eosin. 
Seneca Valley virus-specific nucleic acid detection  
Samples were extracted using the MagMAX™ Pathogen RNA/DNA kit (Life 
Technologies, Carlsbad, CA) following manufacturer’s recommendations and a MagMAX™ 
Express instrument 24 (Life Technologies) using program AM1836 (Life Technologies). The 
viral RNA was eluted in 90 µL of elution buffer. Following extraction, 5 µL of the nucleic acid 
templates were added to 20 µL of the Path-ID™ Multiplex One-Step RT-PCR reaction master 
mix (Applied Biosystems, Foster City, CA) for fecal swabs or 20 µL AgPath-ID™ One step RT-
PCR kit (Applied Biosystems) for nasal swabs, vesicle fluids, and sera. The primers and probe 
were designed to target the conserved region between the 5’ untranslated region (5’UTR) and 
protein L containing nucleotides 602-710 of the SVA genome. The forward primer sequence was 
5'-TGCCTTGGATACTGCCTGATAG-3’, the reverse primer sequence was 5'-
GGTGCCAGAGGCTGTATCG-3’ and the probe sequence was 5'-CGACGGCCTAGTCG 
GTCGGT T-3’. The probe was labeled using 6-FAM™ at the 5’ end, ZEN™ internal quencher, 
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and Iowa Black® quencher at the 3’ end (Integrated DNA Technologies, Coralville, IA). Real-
time RT-PCR was performed on an ABI 7500 Fast instrument (Life Technologies) run in 
standard mode with the following conditions: 1 cycle at 48 °C for 10 min, followed by 1 cycle at 
95 °C for 10 min, and 40 cycles of 95 °C for 15 sec and 60 °C for 45 sec. SVA genome RNA 
copies were calculated based on a standard RNA transcript overlapping the target region. 
Indirect immunofluorescence (IFA) assay  
SVV-specific IgG antibody response to SVV challenge was evaluated by an IFA assay. 
Serum samples were serially diluted 1:2 up to (1:5120). Plates were previously prepared with 
SVV-infected NCI-H1299 cells overnight and fixed with cold 80% acetone, and stored at -20 °C. 
Plates were rehydrated with 200 µL of PBS and 50 µL of diluted serum were added to wells to 
incubate for 1 hour. Plates were washed 3 times and 1:50 diluted anti-swine IgG-FITC antibody 
(KPL, MD, USA) was added to incubate for 45 min. Again, plates were washed 3 times and 
wells were observed for fluorescence under a fluorescent microscope. The highest serum dilution 
with clear and specific staining was considered as the end point (i.e., IFA titer). 
Virus neutralization (VN) assay 
Serum samples were heat-inactivated at 56 °C for 30 min and serially diluted 1:4 (up to 
1:4096) in MEM in a 96-well plate and repeated in quadruplicate. Each diluted serum was mixed 
with an equal volume of SVA15-41901SD (200 TCID50) and incubated for 1 hour at 37 °C. One-
hundred microliters of each virus-serum mixture was transferred to respective wells of 96-well 
plates of ST cells grown to a confluent monolayer and replenished with MEM supplemented 
with 2% FBS. Plates were read for CPE daily for 4 days. VN titers, based on CPE, were recorded 
as the highest dilution of serum at which the infectivity of SVA-41901SD was completely 
neutralized in 50% of the inoculated wells. A back titration of the virus was performed during 




Data analyses and graphic representations were performed by using Microsoft Office 
Excel 2010 and GraphPad Prism 7.03. Statistical analyses of the data were performed using a 
mixed linear model (SAS 9.4 for Windows XP, SAS Institute Inc., Cary, NC, USA) for repeated 
measures and a spatial spherical or autoregressive covariance structure was utilized.  Linear 
combinations of the least squares means estimates for GC/uL were used in a priori contrasts after 
testing for either a significant (P<0.05) effect of treatment or a significant treatment by time 
interaction. Comparisons were made between treatment groups at each time-point using 5% level 
of significance (P<0.05) to assess statistical differences.    
 
Ethics approval and consent to participate 
This study was approved and performed in accordance with Institutional Animal Care 
and Use Committee guidelines (ACUP #2867) at the USDA ARS National Animal Disease 
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Abstract 
Senecavirus A (SVA) was discovered as a cell culture contaminant in 2002, and multiple 
attempts to experimentally reproduce disease were unsuccessful. Field reports of porcine 
idiopathic vesicular disease (PIVD) cases testing PCR positive for SVA in addition to outbreaks 
of PIVD in Brazil and the United States in 2015 suggested SVA was a causative agent, which 
has now been consistently demonstrated experimentally. Ease of experimental reproduction of 
disease with contemporary strains of SVA raised questions concerning the difficulty of 
reproducing vesicular disease with historical isolates. The following study was conducted to 
compare the pathogenicity of SVA between historical and contemporary isolates in growing 
pigs. Six groups of pigs (n=8) were intranasally inoculated with the following SVA isolates: 
SVV001/2002, CAN/2011, HI/2012, IA/2015, NC/2015, SD/2015. All isolates induced vesicular 
disease in at least half of the inoculated pigs from each group. All pigs replicated virus as 
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demonstrated by serum and/or swab samples positive for SVA by quantitative PCR. Pig sera 
tested by virus neutralization assay demonstrated cross-neutralizing antibodies against all viruses 
utilized in the study. Cross-neutralizing antibodies from pigs inoculated with historical isolates 
were lower than those pigs that were inoculated with contemporary isolates. Phylogenetic 
analysis revealed two clades with SVV001/2002 being in a separate clade compared to the other 
five isolates. Although differences in the infection kinetics and sequences of these six isolates 
were found, clinical presentation of vesicular disease was similar between both historical and 
contemporary isolates.  
 
Introduction 
Senecavirus A (SVA) is a non-enveloped, positive-sense, single-stranded RNA virus ~7.2 
kb in length (1). SVA is the only member of the genus Senecavirus in the family Picornaviridae 
and shares closest sequence identity to the genomes of those viruses in the Cardiovirus genus 
(2). SVA has one large open reading frame (ORF) encoding a single polyprotein that is then 
cleaved by viral proteases into 12 mature proteins in the standard picornavirus L-4-3-4 layout 
(1). The icosahedral viral capsid consists of 60 protomers each containing the structural proteins 
VP1, VP2, VP3, and VP4 (located internally) with lengths of 265, 286, 241, and 74 amino acids 
(AA) respectively (3). The single ORF is flanked by a long 5’untranslated region (UTR) (666 
AA) and short 3’UTR (71 AA) followed by a poly(A) tail (4).  
SVA was first discovered as a cell culture contaminant at a lab in Maryland in 2002 and 
was named Seneca Valley virus-001 (SVV-001) (1). The source of contamination was speculated 
to be porcine trypsin or fetal bovine serum (5). Picornavirus-like viruses had been isolated from 
sporadic swine samples at the National Veterinary Services Laboratory (NVSL) beginning in 
1988 from various locations across the United States and clinical histories (2). These isolates 
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were sequenced and shown to be closely related to SVV-001, supporting the role of swine as a 
natural host. Knowles et al. used two of the historical isolates to inoculate pigs, but was 
unsuccessful in demonstrating specific clinical disease (2).  
In 2007, a load of market hogs being transported from Canada into the United States 
contained animals presenting with lameness and vesicular lesions on the snouts and coronary 
bands (6). These animals were diagnosed with porcine idiopathic vesicular disease (PIVD) after 
testing negative for the top differentials of infectious causes of vesicular disease in swine 
including foot-and mouth disease virus (FMDV). Interestingly, samples from these animals did 
test positive for SVA by reverse transcriptase polymerase chain reaction (RT-PCR). In 2012, 
Yang et al. inoculated four pigs with a SVA isolate received from NVSL. Although all pigs 
developed a viremia and an antibody response, no specific clinical disease was observed. 
Subsequently, a case report of a single boar in Indiana with vesicular disease was published and 
again samples tested PCR positive for SVA (7). Thus, experimental reproduction of specific 
disease with SVA continued to be unsuccessful, but field cases provided additional evidence 
vesicular disease was associated with SVA infection in pigs.  
Starting in late 2014 and into 2015 several states in Brazil reported a sharp increase in 
cases of PIVD and an increase in pre-weaning mortality (8, 9). Samples from these cases tested 
positive for SVA, which was the first detection of the virus in Brazil. Subsequently, similar cases 
emerged in the United States in the summer of 2015 (10, 11). With mounting evidence 
supporting SVA as a causative agent for vesicular disease in swine, multiple experimental 
studies were performed and reproduced vesicular disease after SVA inoculation (12-14). The 
success in demonstrating disease across various age groups, led to questions regarding previous 
attempts that were unable to show specific disease in pigs exposed to SVA. Some areas of 
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speculation were differences in pathogenicity of the viruses, susceptibility of the host, or the 
requirement of a novel co-factor.  
Since questions still remain about the pathogenicity of historical isolates, the objectives 
of this study were to detail infection dynamics of three historical and three contemporary SVA 
isolates in swine, characterize cross-neutralizing antibody responses, and compare SVA genomic 
sequences.  The hypothesis was that historical SVA strains isolated prior to the 2015 outbreak in 
the US would be less pathogenic than contemporary isolates in swine. 
Materials and Methods 
Cells and virus  
A swine testicular (ST) cell line was cultured at 37 °C and 5% CO2 in Minimum 
Essential Medium (MEM, MilliporeSigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum (FBS, AtlantaBio, Flowery Way, GA), gentamicin (VetOne/MWI, Boise, ID) and L-
glutamine (Life Technologies, Carlsbad, CA). ST cells were used for virus titration and virus 
neutralization assays. Although ST cells may not grow SVA to as high of titers as other 
susceptible cell lines (15), they were utilized due to their susceptibility and the ease of reading 
cytopathic effect (CPE) microscopically (16). 
Six isolates of SVA were used in the study. A brief history of each isolate is as follows. 
SVV001/2002 was the original cell culture contaminant strain SVV-001 purchased from the 
American Type Culture Collection (ATCC PTA-5343) and was passaged in cell culture three 
times (p3). CAN/2011 was obtained from NVSL originally isolated from a swine brain with 
origins in Canada and a history of vesicular disease (p2). HI/2012 (NADC40) was isolated from 
serum of a pig in Hawaii exhibiting vesicular disease by the Agriculture Research Service 
National Animal Disease Center (NADC) (p2). SD/2015 was isolated from vesicular fluid of a 
pig inoculated with SVA15-41901SD (p2) (10, 17). IA/2015 was isolated from samples collected 
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from a vesicular disease case in finishing pigs located in Iowa (p7). NC/2015 was isolated from a 
swine sample submitted to the Kansas State Veterinary Diagnostic Laboratory from North 
Carolina with no clinical history of vesicular disease (p4). Subsequent next-generation 
sequencing (NGS) and PCR revealed the presence of porcine respiratory coronavirus 
contamination in the viral stock of NC/2015. NC/2015 was received with a titer around 105 
TCID50/mL, while the remaining isolates had titers around 107 TCID50/mL calculated using the 
Reed and Muench method (18). Therefore, the viral stock of NC/2015 was diluted 1:2 with 
MEM, while the remaining viruses were diluted 1:5 with MEM for inoculum preparation (5 
mL/animal).  
Animals and experimental design 
Study pigs were farrowed at the NADC from sows purchased from a commercial source 
in Wisconsin, USA. All research was performed in accordance with an approved NADC Animal 
Care and Use Protocol (ACUP 2867). All pigs were clinically free of lesions, negative for SVA 
by PCR in serum and rectal swabs, and seronegative at the start of the study. Animals were 
housed under ABSL-2 conditions for the experiment. Fifty-four pigs ranging in age from 5-6 
months were placed into one of six treatment groups (n=8 per group) and one control group 
(n=6) based on ear tag number blocking by litter. Each treatment group was housed in a separate 
room for the experiment.  
Animals in treatment groups were inoculated intranasally with 5 mL of inoculum around 
107 TCID50/mL except for the NC/2015 group that received 105 TCID50/mL on 0 days post 
inoculation (0 dpi) split between both nostrils. Animals were bled and oral swabbed on 0, 4, 7, 
and 14 dpi. Rectal swabs and observations for vesicle development and lameness were 
performed daily between 0-11 and on 14 dpi. All animals were humanely euthanized at 14 dpi 
with an intravenous dose of barbiturate (Fatal-Plus® Solution, Vortech Pharmaceuticals, 
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Dearborn, MI) according to the manufacturer label dose. One animal in the SVV001/2002 group 
had to be euthanized prior to the start of the study due to health issues.   
Sample collection and lesion scoring  
Pigs were manually restrained for blood collection via jugular venipuncture and blood 
was transferred into serum separator tubes (BD Vacutainer®, Franklin Lakes, NJ). Tubes were 
centrifuged for 10 min at 920 x g to harvest the serum. Oral and fecal swabs were collected using 
a sterile polyester tipped applicator (Puritan Medical Products, Guilford, ME), immersed in 3 mL 
of serum-free MEM. All samples were stored at -80 °C for future testing.  
Vesicular lesions present on the coronary bands and snout were scored with a 5 point 
system: each foot that displayed a vesicular lesion was given 1 point and a vesicle on the snout 
was assigned 1 point. An animal was given a score of zero if no lesions were identified. Average 
lesion score was calculated by adding up the scores for each pig in a group divided by the total 
number of pigs in the group.    
SVA nucleic acid quantification 
Serum and swab samples were extracted and tested by real-time RT-PCR (RT-qPCR) as 
previously described (17). Briefly, RNA was extracted from samples using the MagMAX™ 
Pathogen RNA/DNA kit (catalog no. 4462359; Applied Biosystems, Waltham, MA) following 
manufacturer’s recommendations. Next, 5 µL of extracted product was added to 20 µL of the 
Path-ID™ Multiplex One-Step RT-PCR reaction master mix for fecal swabs or 20 µL AgPath-
ID™ One step RT-PCR kit for oral swabs, vesicle swabs, and sera (Applied Biosystems). The 
primers and probe were designed to target a conserved region containing nucleotides 602-710 of 
the SVA genome. The forward primer sequence was 5’-TGCCTTGGATACTGCCTGATAG-3’, 
the reverse primer sequence was 5’-GGTGCCAGAGGCTGTATCG-3’ and the probe sequence 
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was 5’-CGACGGCCTAGTCGGTCGGTT-3’. RNA copies were calculated based on a plasmid 
containing the target region and Ct values greater than 35 were considered negative. 
Virus neutralization (VN) assay  
Sera from challenged animals were tested by VN assay to determine neutralizing 
antibody response to the challenge strain in addition to cross-neutralizing titers against all other 
viruses utilized in the study. Serum samples were heat-inactivated at 56 °C for 30 min, serially 
diluted 1:4 (up to 1:4096) in MEM, and run in quadruplicate. An equal volume of diluted 
SVV001/2002, CAN/2011, HI/2012, SD/2015, IA/2015, or NC/2015 (~200 TCID50) was added 
to the serum and incubated for 1 hour at 37 °C. The virus-serum mixture was transferred to 96-
well plates of ST cells grown to a confluent monolayer containing MEM supplemented with 2% 
FBS. Plates were microscopically evaluated for cytopathic effect (CPE) daily for 4 days. Titers 
were recorded as the highest dilution of serum at which the infectivity of the SVA isolate was 
completely neutralized in at least 50% of the inoculated wells. VN assays using each SVA isolate 
were performed on all 14 dpi serum samples during one run with a back-titration of the viral 
solution. Viruses were titrated during each run and ranged from 30-500 TCID50/well. Sera from 0 
dpi was only tested against the homologous strain of SVA. Virus neutralization titers of ≤1:16 
were considered negative (19). The geometric mean of the 7 or 8 pigs in each treatment group 
was calculated for comparison of cross-neutralizing titers.  
Sequencing 
One sample from each of the six treatment groups was selected for virus isolation based 
on the highest number of genomic copies present in either serum or swabs as determined by RT-
qPCR (4-7dpi). To ensure adequate viral genetic material was present for sequencing, 
supernatant from cell cultures was collected 48 hours after a monolayer of ST cells was 
inoculated with sample and total RNA was extracted from the supernatant of the second passage 
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using the NucleoSpin Virus Kit (Clontech, Takara Bio Inc.). A RT-PCR assay was performed 
using primers designed from the original SVV-001 sequence in GenBank (NC_011349). PCR 
products were run on an agarose gel to purify bands of interest. Bands were removed and 
fragments were cloned into a pCR™4Blunt-TOPO® vector (catalog no. 45-0031, Invitrogen). 
Cloned products were then sent to Iowa State University DNA Facility and the sequencing 
facility at NADC for Sanger sequencing. Sanger runs were done in duplicate from each direction 
using multiple plasmids for each sequenced segment. Any gaps remaining in the sequence were 
filled by developing new specific primers for the target and repeating the same procedure to 
complete the sequence (Supplemental Table 1). The 3’ and 5’ ends of the sequences were 
completed using 3’ (TAKARA SMARTer® RACE 5’/3’ Kit) and 5’ (Invitrogen™ 5' RACE 
System for Rapid Amplification of cDNA Ends, version 2.0) RACE kits according to the 
manufacturer instructions. Sequences have been added to GenBank (MT360257-MT360262).  
Sequences of challenge isolates (i.e., inocula) were also obtained for comparison to 
Sanger sequencing of animal isolates. Three inoculum strains had already been deposited into 
GenBank: SVV001/2002 (KU954086), CAN/2011 (KC667560), and SD/2015 (KU051394). The 
sequence for IA/2015 was provide by the collaborator. Cell culture supernatant samples from 
HI/2012 and NC/2015 were sent to Iowa State University for next generation sequencing (NGS) 
using the Illumina platform. In addition, the animal viral isolate for CAN/2011 was sent for NGS 
sequencing for confirmation due to laboratory error during the Sanger sequencing process. 
Library preparation, sequencing, and sequencing data analysis methods were performed 
following previously published methods (20, 21). 
Analysis  
Data analyses and graphic representations were performed by using Microsoft Office 
Excel 2010 (Microsoft, Bellevue, WA, USA) and GraphPad Prism 8.1.2 (San Diego, CA, USA), 
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respectively. Complete genome nucleotide sequences were first generated from sequence reads 
using Lasergene 11 (DNASTAR, Inc., Madison, WI, USA). Illumina NGS sequence reads were 
assembled and analyzed, and final nucleotide alignments were generated using the MAFFT 
algorithm (22, 23), in Geneious Prime Version 2020.0.4 (Biomatters Ltd, Auckland, New 
Zealand). Phylogenetic examination was completed using RAxML using the GTR Gamma 
Nucleotide Model and the Rapid Bootstrapping (x500) and search for the best-scoring Maximum 
Likelihood Tree Algorithm with a random parsimony seed of one (24) available in Geneious. 
The output tree was imported into FigTree v1.4.3 for optimal display 
(http://tree.bio.ed.ac.uk/software/figtree/).  
Venkataraman et al. reported the residues from each of the structural proteins that make 
up the most prominent loop structures of SVV, which can help determine cell tropism for 
picornaviruses as well as antigenic sites that elicit immune responses to infection (3, 25). The 
prominent loops analyzed for AA changes between the six SVA isolates in this study are as 
follows: BC loop of VP1 (VP1 residues 50-74, P1 residues 724-748), Loop II or CD loop of VP1 
(94-109, 768-783), GH loop of VP1 (185-215, 859-889), “the puff” of VP2 (172-200, 323-351), 




Animals from every treatment group developed clinical signs of vesicular disease, while 
control animals did not. No other clinical signs such as lameness, lethargy, or inappetence were 
observed during the study. Vesicular lesions on the coronary band were more common than 
those on the snout. Only 2 pigs in this study developed snout lesions. The number of animals that 
developed lesions in each group ranged from 5-8 pigs (62.5%-100%). Vesicular lesions were 
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visually similar between pigs infected with historical isolates compared to contemporary isolates 
(Figure 1A-C).  
A score out of five was assigned to each animal to score gross lesions and an average was 
calculated for all pigs in each group daily (Figure 1D). All pigs (8/8) inoculated with SD/2015 
and HI/2012 developed lesions and these isolates had the highest average lesion score by the end 
of the study. The lowest average lesion score was in pigs inoculated with NC/2015 with 6/8 pigs 
developing vesicles. There was a range in onset of vesicle development between the 6 treatment 
groups. The two oldest isolates in the study, SVV001/2002 and CAN/2011, had the fastest onset 
of clinical signs with the first pig to develop a vesicle at 3 and 2 dpi, respectively. The two 
viruses with the slowest onset of lesion development were SD/2015 and HI/2012 starting at 7 
and 9 dpi respectively. Pigs inoculated with IA/2015 and NC/2015 developed clinical signs 
beginning at 4 dpi.  
  
Figure 4.1: Clinical disease in inoculated animals. A) Intact coronary band lesion observed in a pig 
infected with a historical isolate on 2 dpi and ruptured coronary band lesion in another pig on 5 dpi. B) 
Intact coronary band lesion observed in a pig infected with a contemporary isolate on 5 dpi and an intact 
coronary band lesion in another pig on 7 dpi. C) Snout lesion on a pig infected with a contemporary 
isolate on 5 dpi D) Animals were scored on a scale of 0-5. Average lesions scores plotted for each group. 
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SVA RNA Detection  
RT-qPCR was performed on serum and swab samples. All selected samples from control 
animals tested negative for SVA RNA by PCR. All animals in treatment groups were negative 
for SVA in all samples on 0 dpi.   
Peak viremia for all groups occurred at the 4 dpi sample except NC/2015, which peaked 
at the 7 dpi sample time point (Figure 2A). None of the animals in the study remained viremic on 
14 dpi. All animals in SD/2015, NC/2015, and HI/2012 groups had a detectable viremia on at 
least one sampling time point. In the CAN/2011 group 6/8 animals had PCR positive serum. 
Finally, only 4/8 and 3/7 animals in IA/2015 and SVV001/2002 treatment groups, respectively, 
had a detectable viremia during the study. The lowest levels of viremia were detected in pigs 
challenged with SVV001/2002.  
RNA levels in oral swabs peaked during the first week after inoculation with levels 
reducing on 14 dpi (Figure 2B). All animals in treatment groups had at least one RT-qPCR-
positive oral swab and a majority of the animals still had positive oral swabs on 14 dpi. In 
addition, all animals in this study had a least one PCR-positive rectal swab. CAN/2011 animals 
had high levels during the first few days after inoculation and peaked at 5 dpi (Figure 2C). 
SVV001/2002 had a similar levels compared to CAN/2011. In contrast, SD/2015, NC/2015, and 
HI/2012 peaked later in the study around 10 dpi and had the higher levels in the second half of 





Figure 4.2: Viral load as detected by RT-qPCR in A) serum, B) oral swabs, and C,D) rectal swabs. 
Rectal swab results were split into a graph for historical isolates (C) and a graph for contemporary isolates 
(D). Bars represent a mean of all 7 or 8 pigs in a group. Error bars are standard error of the mean. The 
legend contains the color code to all six viruses.  
SVA neutralizing antibodies  
A virus neutralization assay was run on 0 and 14 dpi serum for all animals to assess 
neutralizing and cross-neutralizing titers. All animals had titers ≤1:16 (i.e., seronegative) on 0 
dpi and developed a neutralizing antibody response against the homologous isolate in addition to 
cross-neutralizing titers against all other isolates used in this study by 14 dpi (Table 1). A 
geometric mean was calculated for all animals in each group. Pigs inoculated with SVV001/2002 
had the lowest cross-neutralizing titers compared to animals inoculated with other strains, though 
serum from the CAN/2011 group also had low cross-neutralizing titers. Serum from pigs 
inoculated with SD/2015 and IA/2015 performed similarly on the VN assay against all viruses. 
Serum from pigs inoculated with NC/2015 and HI/2012 also performed similarly against all 
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viruses. Most treatment groups had high neutralizing titers against SD/2015 and IA/2015. In 
contrast, most groups had low cross-neutralizing titers to SVV001/2002, HI/2012, and NC/2015.  
Table 4.1: Virus neutralization assay results for 14 dpi serum against all six viral isolates. 
*Columns represent virus used to inoculate pigs 
#Rows represent virus used in the virus neutralization assay 
^Numbers in the boxes represent the geometric mean of the titer from virus neutralization assay results 
for all pigs in each group. 
 
SVA sequence comparison and phylogenetics  
The complete genome was sequenced from virus isolated from animal samples 
representing all 6 treatment groups in this study via Sanger sequencing methods to demonstrate 
the virus being shed from the animals was the same virus used for inoculation. The sequences 
obtained from animal samples had 99.8% nucleotide identity or greater to their respective 
inoculum strains sequenced by next-generation sequencing (NGS). Three inoculum strains had 
already been deposited into GenBank: SVV001/2002 (KU954086), CAN/2011 (KC667560), and 
SD/2015 (KU051394). The percent nucleotide identity among all isolates was 93.7% or greater 
(Table 2). If SVV001/2002 and CAN/2011 (95.1% nucleotide identity) were removed the 
remaining isolates would have a 97.9% nucleotide identity. SD/2015 and IA/2015 were the most 
similar with a nucleotide identity of 99.2% with a difference of only 58 nucleotides. 
Pig antiserum SD/2015* IA/2015 NC/2015 HI/2012 CAN/2011 SVV/2002 
SD/2015# 1722^ 2896 1448 1448 609 464 
IA/2015 2048 2048 1024 1722 724 380 
NC/2015 431 512 609 724 152 64 
HI/2012 609 609 431 724 181 95 
CAN/2011 609 861 1024 1448 1024 210 




SVV001/2002 and IA/2015 had the most differences with a nucleotide identity of 93.7% and a 
difference of 456 nucleotides with those differences spread throughout the genome. A 
comparison of the six SVA isolates to a consensus sequence can be seen in Figure 3, which also 
supports the conclusion that SVV001/2002 and Can/2011 share a low nucleotide identity with 
the remaining four isolates. 
Table 4.2: Distance matrix and heat map for the SVA genomes included in this study. 
 
* Numbers above the 100% nucleotide identity bars (black) are the numbers of nucleotide differences 
between the genomes 
#Numbers below the black bars are % nucleotide identities between the genomes  
 
 
Figure 4.3: Graphic representation of the SVA genome comparisons to the consensus sequence. 
Nucleotides representing the 5’-UTR and primary polyproteins (P1, P2, P3) are indicated above, and the 
predicted final processed ORFs are shown below the consensus sequence. Vertical lines represent 
differences when compared to the consensus sequence when viewed with a strict threshold of 50%. One 
undescribed open reading frame (ORF?) defines an ORF of 249 nt (83 aa) in sequences #2-6, and a much 
smaller ORF of 36 nt (13 aa) in sequence #1 (SVV001). 
 SVV/2002 Can/2011 HI/2012 NC/2015 SD/2015 IA/2015 
SVV/2002  357* 403 430 447 457 
Can/2011 95.1#  219 270 283 293 
HI/2012 94.5 97.0  145 149 154 
NC/2015 94.1 96.3 98.0  89 101 
SD/2015 93.9 96.1 98.0 98.8  58 




Prominent loop structures in the capsid of SVA can help determine receptor binding and 
serve as B cell epitopes. AA changes between the six isolates in these structures are as follows. 
The BC loop of VP1 (residues 724-748) had 3 non-conservative AA changes between the 
isolates compared to the consensus sequence (Figure 4). Two changes were present in 
SVV001/2002, while CAN/2011, HI/2011, and IA/2015 had one change. Only one non-
conserved AA difference was found in Loop II (CD loop, residues 768-783) of VP1 again in 
SVV001/2002. The GH loop of VP1 (residues 859-889) and “the puff” of VP2 (residues 323-
351) did not have any non-conservative AA differences between the isolates. Finally, “the knob” 
of VP3 (residues 492-508) had 4 non-conservative AA differences from the consensus sequence. 
All four positions could be found in SVV001/2002. CAN/2011 and HI/2012 had 1 AA change 
the same as SVV001, but in contrast the contemporary isolates all had a different AA change in 
the same position.  
Phylogenic analysis was completed after all available full-length genomes (220) in 
GenBank were downloaded and aligned (03/30/2020). The midpoint rooted dendrogram revealed 
a major shift in phylogeny between 2002 and 2005 and development of a new clade of viruses 
(Figure 5). Clade 1 represents older SVA isolates and Clade 2 represents newer viruses. 
SVV001/2002 is located in Clade 1 while the remaining 5 isolates are found in Clade 2. The 
other five isolates are spread throughout Clade 2, though IA/2015 and SD/2015 fall closer 
together than the others. Interestingly, NC/2015 fell into the same branch as an isolate from 
Colombia from 2016. SVV001/2002, CAN/2011, and SD/2015 were grouped with the viruses 






Figure 4.4: Graphic representation of the amino acid alignment for SVA P1 protein region. There are many other amino acid 
differences elsewhere in the genome. The consensus sequence is color coded by amino acid residue and colors are shown in the 
legend. Prominent loop structures are also indicated. The amino acids representing primary polyproteins P1 is indicated above, and the 
predicted final processed VPs are shown below the consensus sequence. Vertical lines represent differences when compared to the 




Figure 4.5: Phylogenetic analysis (midpoint rooted, increasing node order) of 220 SVA genomes 
available in GenBank along with the six genomes sequenced in this study. CA2011, HI2012, 
NC2015, SD2015, IA2015 are shown in blue typeface, while the re-sequenced index strain SVV-





Recently, Fernandes et al. compared pigs inoculated with the original cell culture 
contaminant, SVV-001, to those inoculated with a US contemporary isolate from 2015 (26). 
They reported that pigs inoculated with the historical isolate did not show signs of vesicular 
disease, but inoculation did result in infection and antibody response (26). In addition, another 
study compared the pathogenicity of two Chinese contemporary isolates (2016 vs 2017) and 
found one isolate to be more pathogenic in pigs than the other (27). To further explore 
pathogenicity differences between SVA strains, this study compared three strains isolated prior 
to the outbreak of SVA in both Brazil and the US in 2015 and three more isolated during the 
outbreak.  
Whether pigs were inoculated with a historical isolate or a contemporary isolate, a 
majority of the animals in each treatment group developed vesicular lesions. In the 
SVV001/2002 group, 5/7 animals developed clinical signs of vesicular disease. This study is in 
contrast to a recent pig study that reported they did not observe vesicular disease in those animals 
inoculated with a SVV-001 isolate, though they did observe lesions in animals inoculated with a 
2015 SVA isolate (26). Both research groups purchased the SVV-001 isolate from ATCC. In this 
study 5-6-month-old pigs were challenged intranasally with 5 mL of inoculum with a titer of 
>105 TCID50/mL, while the other study challenged 4-month-old pigs oronasally with 10 mL of 
inoculum (5 mL orally and 5 mL intranasally) with a titer of 107.5 TCID50/mL. Both studies had 
experimental groups of similar size and animals close in age, though genetic differences are 
unknown. Fernandes et al., used H1299 cells, a human cancer cell line, to grow the virus while 
this study used a swine cell line (ST cells). Passage on swine cells versus human cells could have 
aided virus adaptation to pigs. In addition, ST cell culture supernatant collected for viral stock 
solutions may contain a factor that contributes to virus pathogenicity. These differences may 
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have contributed the contrasting reports of clinical disease development after challenge with 
SVV-001.  
Field observations of SVA infections at farms have reported a large range of percentage 
of animals developing vesicular lesions during an outbreak (8, 28). It has also been reported that 
clinically affected sows had a similar proportion of PCR positive samples compared to non-
clinically affected sows (29). Thus, providing evidence that even current circulating isolates of 
SVA in the field do not cause clinical disease in all infected animals, which is supported by a 
seroprevalence study in the US suggesting SVA is circulating subclinically (30). In addition to 
viral factors, there could be external factors such as skin abrasions or friction that contribute to 
the development of vesicular lesions and location whether on the coronary bands or snout. Pigs 
in this study were housed on a flat concrete floor which may have been more abrasive than other 
flooring used in animal research housing such as raised decks. NC/2015 was isolated from a 
diagnostic sample from pigs not showing clinical signs of vesicular disease, but in this study 
when inoculated into pigs it did cause vesicular disease. Further work should be performed to 
understand viral pathogenesis and why some animals develop lesions after SVA infection, while 
others do not. 
Since the inoculums utilized in this study did not have identical titers, it is difficult to 
make direct comparisons of quantitative PCR results from serum and swabs, but some general 
conclusions can be drawn. All animals in this study replicated virus and had detectable nucleic 
acid in serum, oral swabs and/or rectal swabs. This is in agreement with previously reported 
work with SVV-001 and a 2015 isolate; though, they also reported lower virus levels in serum in 
pigs challenged with SVV-001, but similar levels in oral and fecal swabs (26).  This study 
similarly found lower levels of virus in the blood of pigs inoculated with SVV001/2002 
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compared to other treatment groups in the study. Since, this virus was discovered as a cell culture 
contaminant it may be cell culture adapted and replicate less efficiently in pigs compared to the 
other isolates that were obtained from pig samples. This research supports previous work 
reporting a short viremia and in this study some pigs did not develop a detectable viremia after 
inoculated with SVA, which indicates that serum may not always be relied upon alone to detect 
SVA infection (13, 31). 
Interestingly, CAN/2011 had the highest levels of virus detected by PCR in rectal swabs 
for the first 3 days after inoculation and this group was the first to develop clinical signs of 
vesicular disease. In addition, pigs in both HI/2012 and SD/2015 groups were the latest to 
develop vesicles and timing coincided with later peaks in shedding of virus detected by rectal 
swabs. High levels of virus detected in rectal swabs may coincide with higher levels of viral 
replication in keratinocytes of the epidermis of the coronary bands and snout leading to vesicle 
development. Due to the timing of increased shedding in rectal swabs with lesion development in 
some groups, rectal swabs may be a reliable sample to collect besides lesion swabs during a 
disease break when lesions are observed.  
VN results demonstrated that animals developed neutralizing antibody titers against the 
homologous virus as well as cross neutralizing titers against heterologous viruses used in the 
study suggesting SVA has a single serotype. SVV001/2002 animals had the lowest cross-
neutralizing antibody titers. Fernandes et al., also reported lower neutralizing antibody titers in 
pigs inoculated with SVV-001 compared to a 2015 isolate (26). SVV001/2002 is the most 
genetically distinct from the other viruses used in this study, thus amino acid changes in the 
capsid proteins resulting in altered neutralizing epitopes could explain the lower cross-
neutralizing titers. It is still unknown what titer of neutralizing antibody provides protection for 
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an animal, so lower titers could still provide protection against viral challenge. In addition, others 
have studied the cell-mediated immune response, which also plays a role in protection (26, 31). 
Future studies utilizing heterologous challenge models would help discern if lower cross-
neutralizing antibodies are still protective against challenge. 
Sequencing results supported that the inoculum virus was the same virus that was isolated 
from animal samples. Sequences from animal isolates only had a few base substitutions 
compared to the inoculum, thus showing that one passage in a pig and a passage through cell 
culture did not drastically alter the viral genome. It has been reported that RNA viruses have a 
mutation rate ranging from 10-6 to10-4 substitutions per nucleotide per cell infection (s/n/c) (32). 
Information from these 2 passages support that rate. SVV001/2002 is the only isolate that was 
not collected directly from a swine sample and was older than all other isolates by ten years. The 
combination of these factors and others may explain its genetic distance from other SVA 
isolates.  
Although these 6 viruses are genetically similar, the AA sequences of some of the most 
prominent loop structures of the structural proteins on the capsid of the virus did have some AA 
differences. Though there were not many AA changes, they could play a role in altering structure 
and explain some of the differences observed in neutralizing titers reported in this study. The BC 
loop and loop II of VP1, “the puff” of VP2, and “the knob” of VP3 were picked out for further 
evaluation since they have been shown to interact with the SVA receptor ANTXR1 and similar 
regions have been shown to be involved in neutralizing epitopes for FMDV and other 
picornaviruses (33, 34). Other linear B cell epitopes on VP1 and VP2 have recently been 
reported; thus, further examination of changes between SVA isolates in the capsid proteins is 
necessary (35).  
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Although previous studies were unable to experimentally reproduce vesicular disease in 
swine after SVA inoculation with historical isolates, pigs inoculated with SVV001/2002, a cell 
culture isolate, developed vesicular disease in this study. This research also demonstrated two 
other isolates from prior to 2015 were able to induce vesicular lesions similar to contemporary 
isolates; however, these strains were isolated from pigs that presented with lesions. Conflicting 
reports about the ability of SVV-001 to cause clinical disease support the need for additional 
research to better understand viral factors contributing to pathogenicity of SVA and host factors 
contributing to development of vesicular disease in swine.  
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Abstract 
Senecavirus A (SVA) is a picornavirus that causes vesicular disease in swine. With the 
spread of SVA around the globe, some countries free of foot-and-mouth disease (FMD) are 
experiencing an endemic vesicular disease in their swine populations, which adds to the time and 
cost burden of ruling out FMD every time a vesicle is observed since FMD and SVA are 
clinically indistinguishable. Understanding the pathogenesis of the virus and its ability to 
transmit to naïve populations is critical to formulating control and prevention measures. The 
primary objective of this study was to determine the infectious dose of SVA in finishing pigs and 
neonates. A 2011 SVA isolate was serially hundred-fold diluted to create four challenge 
inoculums ranging from 106.5 to 100.5 TCID50/mL. Four finishing pigs individually housed were 
intranasally inoculated with 5 mL of each dose (n=16). For neonates, serial ten-fold dilutions 
were used to create 6 challenge inoculums ranging from 105.5 to 100.5 TCID50/mL. Again, four 
animals in individual housing were challenged orally with 2 mL of each dose (n=24). Detection 
of SVA by PCR in collected samples and/or neutralizing antibody response was utilized to 
classify an animal as infected. The minimum infectious dose (MID) for this study in market 
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weight animals was 1,260 TCID50/mL (103.1 TCID50/mL) and similarly for neonates it was 316 
TCID50/mL (102.5 TCID50/mL). Information on the infectious dose provides information that can 
guide biosecurity and disinfections measures to control the spread of SVA.  
 
Introduction 
Senecavirus A (SVA) is a small, non-enveloped, single-stranded, positive-sense RNA 
virus in genus Senecavirus and family Picornaviridae (1). It was originally discovered as a cell 
culture contaminant in 2002 and named Seneca Valley virus (SVV-001); although, similar 
picorna-like viruses had been identified in swine samples dating back to the late 1980s 
suggesting circulation of the virus in swine (2, 3). Early experimental inoculation of pigs resulted 
in viral replication and an antibody response but did not produce any specific clinical disease (2, 
4). In late 2014, vesicular disease outbreaks including increased neonatal mortality on sow farms 
occurred in Brazil and similar cases were reported in the United States (US) in 2015 with 
diagnostic testing confirming the presence of SVA (5-8). Evidence from the field and 
experimental reproduction of vesicular lesions in pigs from weaning to breeding age 
demonstrated that SVA was a causative agent for vesicular disease in swine (9-12).  
 In addition to vesicular disease, both Brazil and the US reported increases in neonatal 
mortality on affected farms with clinical signs including lethargy, wasting, and occasionally 
diarrhea, but Brazil also reported vesicular lesions and neurologic signs in neonates not 
commonly observed in the US (13-15). Further testing in many cases ruled out other causative 
agents for the clinical signs observed, thus leading to the conclusion that SVA was also the cause 
of mortality in piglets on affected breeding farms. Currently, there have been no published 
reports of experimental reproduction of neonatal morbidity or mortality with SVA. 
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SVA has been isolated from environmental samples on swine farms including dust from 
fans, hallways in barns, and even the ground outside barns providing evidence of humans serving 
as fomites to spread the virus around swine facilities (16). In addition, it has been isolated from 
environmental samples taken from an assembly yard for animals prior to shipment to slaughter 
(17). A recent study found a significant number of cull sows entered multiple collection points 
prior to reaching a slaughter facility making the cull sow network a likely area of pathogen 
transmission (18). Not only has SVA been found on environmental surfaces, but also in mouse 
feces and flies providing additional vectors for the spread of virus (16). Demonstration of virus 
in the environment by both PCR and virus isolation has led to the question of whether this virus 
could be infectious to pigs and play a role in transmission. 
Understanding the epidemiology of SVA and ways to control or prevent spread is 
important considering it causes clinical disease identical to foot-and-mouth disease virus 
(FMDV). FMDV is an economically devastating disease not only for FMDV-free countries with 
an introduction event, but also for those countries with endemic virus battling production losses 
and vaccination costs (19). Since FMDV is on the World Organization for Animal Health (OIE) 
list of notifiable diseases, having an endemic vesicular disease in a country free of FMDV also 
costs time and money since every time a vesicular lesion is observed it must be investigated to 
rule out FMDV (20). In the US, cases of vesicular disease due to SVA have been an issue with 
secondary and cull sow markets where collection points are continuous flow and animals are 
consistently co-mingled allowing virus spread and persistence (18).   
Current environmental testing by PCR for SVA can be difficult to interpret due to the 
lack of information about the infectious dose of SVA. The main objective of this study was to 
determine the minimum infectious dose of SVA in both finishing pigs and neonates. An 
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additional goal was determining the correlation between PCR Ct values, tissue culture infectious 
dose (TCID), and swine bioassay. Results from this study can provide context for interpreting 
SVA PCR results especially those collected from environmental samples.  
 
Materials and Methods 
Cells and Virus 
Swine testicular (ST) cells were grown in minimum essential medium (MEM, 
MilliporeSigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS, AtlantaBio, 
Flowery Way, GA), 1% L-glutamine (Life Technologies, Carlsbad, CA), and gentamicin at 37 
°C and 5% CO2. ST cells were used for virus growth, titration, and virus neutralization assays. 
The virus used for animal inoculation was supplied by the National Veterinary Services 
Laboratory (strain 11-55910-3). It was isolated from a swine brain sample collected from a group 
of market hogs traveling to slaughter from Canada to the US that presented with lameness and 
vesicular disease (GenBank KC667560). The isolate was propagated on ST cells with the second 
and third passage being pooled and diluted to a titer of 1x106.5 TCID50/mL, which was termed the 
stock virus (SVA/CAN/2011). 
Inoculum and virus titration 
Inoculum for the finishing pigs was made by serial hundred-fold dilutions of the stock 
virus with MEM to create four challenge inoculums ranging from 106.5 to 100.5 TCID50/mL. 
Inoculum for the neonates was made by serial ten-fold dilutions of the stock virus with MEM to 
create 6 challenge inoculums ranging from 105.5 to 100.5 TCID50/mL. 
Virus titrations were performed on confluent ST cells in a 96-well plate with each well 
containing 100 µL of growth medium. Virus stocks were serially ten-fold diluted in MEM and 
100 µL was added to seven wells in the column of a plate with the remaining well serving as a 
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control for each virus dilution. Plates were incubated and examined microscopically for 
cytopathic effect for four days after inoculation. Viral titers were calculated using the Reed and 
Meunch method (21).  
Animal study design 
All animal research was performed in accordance with an Animal Care and Use Protocol 
(ACUP ARS-2867) approved by the National Animal Disease Center’s (NADC) Institutional 
Animal Care and Use Committee. At the end of study, all animals were humanely euthanized 
with the intravenous administration of a barbiturate (Fatal Plus, Vortech Pharmaceuticals, 
Dearborn, MI) following the label dose (1 mL/4.45 kg).    
Study 1: Sixteen finishing pigs born and raised at the NADC ranging from eight to nine 
months-of-age were randomly divided into 4 treatment groups (n=4/group): 106.5, 104.5, 102.5, and 
100.5 TCID50/mL inoculum. During the two-weeks animals were on study, they were individually 
housed in four ABSL-2 rooms. The same four rooms were used for each treatment group with 
cleaning, disinfection, and drying for 48-96 hours in between groups. Environmental swabs were 
collected weekly to monitor SVA in the environment. The 100.5 treatment group was challenged 
first followed by successively higher titer inoculum groups ending with the 106.5 treatment group. 
Pigs were challenged intranasally with 5 mL of inoculum split between both nostrils on 0 days 
post inoculation (dpi). Pigs were bled on 0, 3, 7, and 14 dpi and rectal swabs were collected daily 
from 0-14 dpi. Pigs were visually assessed for the formation of vesicular lesions on the coronary 
bands or snouts daily.  
Study 2: Thirty piglets were farrowed at NADC from sows purchased from a commercial 
source. Sows were clinically free of lesions and were negative for neutralizing antibodies against 
SVA. At 24-72 hours after birth, piglets were weaned from the sow and blocking by litter were 
randomly allocated to 7 treatment groups. Six treatment groups (n=4/group) were inoculated 
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with 105.5, 104.5, 103.5, 102.5, 101.5, or 100.5 TCID50/mL inoculum respectively. The seventh group 
(n=6) of pigs served as room contamination sentinels. Six ABSL-2 rooms, one for each challenge 
dose, were utilized for the study each containing five isolators and raised deck (Figure 1A). At 
weaning piglets were ear notched, bled, oral swabbed and rectal swabbed prior to placement in 
an individual isolator (-1 dpi) (Figure 1B). Pigs were given 24 hours to acclimate to feeding 
bowls and milk replacer. During feeding, piglets were fed one at a time by opening the feeding 
port, pouring in milk replacer closing the port before moving to the next isolator. The sentinal 
pig was always fed last. Piglets were challenged orally with 2 mL of inoculum on 0 dpi and 
thereafter isolators were only opened to provide milk replacer through the feeding port. On 6 dpi, 
piglets were bled, oral swabbed and rectal swabbed as they were individually removed from the 
isolators (6 dpi) and placed as a group (n=5) onto the raised deck in the room. Serum and rectal 
swabs were also collected on 10 and 14 dpi.  
 
Figure 5.1: Housing for neonatal pig infectious dose study. A) Room set up for each challenge dose. 
Five individual housing units with a raised deck for subsequent group housing. B) Each individual unit 
has a small port used for feeding and holes in the unit for air circulation were covered with filter paper.  
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All animals were observed daily for clinical signs including lameness, lethargy, 
inappetence, and diarrhea. Serum was harvested from serum separator tubes (BD Vacutainer®, 
Franklin Lakes, NJ) used to collect blood. Oral, rectal, and environmental swabs were collected 
using a sterile polyester tipped applicator (Puritan Medical Products, Guilford, ME), immersed in 
3 mL of MEM. Samples were stored in a -80°C freezer for future testing.  
SVA nucleic acid extraction and quantification 
Serum and swabs were tested by real time reverse transcriptase polymerase chain reaction 
(RT-qPCR) as previously described (22). Briefly, RNA was extracted from samples using the 
MagMAX™ Pathogen RNA/DNA kit (Applied Biosystems) following kit instructions for 
sample type. Next, 5 µL of extracted product was added to 20 µL of the Path-ID™ Multiplex 
One-Step RT-PCR reaction master mix (Applied Biosystems) for fecal swabs or 20 µL AgPath-
ID™ One step RT-PCR master mix (Applied Biosystems) for sera and oral swabs. The forward 
primer sequence was 5’-TGCCTTGGATACTGCCTGATAG-3’, the reverse primer sequence 
was 5’-GGTGCCAGAGGCTGTATCG-3’ and the probe sequence was 5’-
CGACGGCCTAGTCGGTCGGTT-3’. Ct values greater than 35 were considered negative. 
A plasmid containing the target region for the primers and probe was used as a standard 
for quantification. A 490 nucleotide region (313-803) from the 5’ untranslated region (5’UTR) 
and protein L of SVV-001 was cloned into the plasmid vector pCI-neo between the restriction 
enzymes XhoI and MluI (Promega, Madison, WI). The plasmid was transformed into One Shot® 
Electrocomp™ cells (Invitrogen, ThermoFisher Scientific) for plasmid propagation on LB agar 
plates with 50µg/mL Kanamycin. A QIAGEN® Plasmid Maxi Kit was used according to 
manufacturer’s instructions for plasmid purification. RNA was quantified with a NanoDrop 
spectrophotometer (ThermoFisher Scientific) and the average nucleic acid quantity from three 
readings was used to calculate genomic copies (GC).  
103 
 
Virus neutralization (VN) assay 
The virus neutralization assay has previously been described (22). In brief, serum 
samples were heat-inactivated and serially diluted 1:4 (up to 1:4096) in MEM with four 
replicates. An equal volume of SVA/CAN/2011 diluted to ~200 TCID50 was added to the serum 
and incubated for 1 hour. The virus-serum mixture was transferred to confluent 96-well plates of 
ST cells. Plates were microscopically evaluated for cytopathic effect (CPE) daily for 4 days. 
Titers were recorded as the reciprocal of the highest dilution of serum at which the CPE of the 




In Study 1, the SVA isolate SVA/CAN/2011 was serially hundred-fold diluted to create 
four challenge inoculums for finishing pigs with theoretical titers ranging between 106.5 to 100.5 
TCID50/mL for the 100 to 10-6 dilutions respectively (Table 1). Table 1 shows the back-titration 
results from the inoculum as well as the Ct value and GC/mL from RT-qPCR. Dilutions from 100 
to 10-4 had higher titers than the theoretical titer. The 10-6 dilution was undetected by TCID50 
assay. Samples were tested in triplicate and the Ct value and GC/mL were calculated as an 
average of the three wells. Inoculum Ct values ranged from 11.0-32.6 which corresponded to 




Table 5.1: Titers, PCR Ct values, and GC/mL of virus dilutions used to inoculate finishing pigs. 
 
All four pigs in the 106.5 treatment group replicated and shed SVA (Table 2). Rectal 
swabs were positive for SVA starting on 1 dpi with peak genomic copies observed on 6 dpi 
(Figure 2A). All animals had multiple positive swabs throughout the study with an average of 7 
positive swabs per animal. In contrast, the 104.5 treatment group did not have positive rectal 
swabs until 4 dpi with a similar peak at 6 dpi, but quickly declined. Animals in this group only 
had 2 positive swabs on average. Both the 106.5 and 104.5 groups had a smaller second peak of 
viral detection at 10 and 9 dpi respectively. One animal in the 102.5 group had a positive rectal 
swab on 7 and 8 dpi. No animals in the 100.5 challenge group had a positive rectal swab.  
Table 5.2: Summary of finishing pig PCR positive status for each sample type throughout the study 
and VN titer for 14 dpi serum. 
  








106.5 100 3,160,000 5,010,000 11.0 9.99E+9 
104.5 10-2 31,600 63,100 18.7 5.35E+7 
102.5 10-4 316 1,260 25.6 4.75E+5 
100.5 10-6 3.16 0 32.6 4.08E+3 
 
Inoculum Serum  Oral swabs Rectal swabs VN titer 
106.5 4/4 4/4 4/4 1024, 1024, 1024, 4096 
104.5 2/4 2/4 4/4 1024, 1024, 1024, 4096 
102.5 1/4 0/4 1/4 ≤16, ≤16, 64, 1024 




One animal from the 106.5 group did not have a detectable viremia, but the other three 
animals had peak SVA RNA levels at 4 dpi sample (Figure 2B). Two animals in the 104.5 group 
and only one animal in the 102.5 group had a detectable viremia (Table 2). Oral swabs taken on 
the same days as the blood samples had very similar PCR results to the serum except that all four 
animals in the 106.5 group had positive oral swabs, while no animals in the 102.5 group tested 
positive (Figure 2C). The same two pigs in the 104.5 group had positive serum and oral swabs. 
Finally, no animals in the 100.5 treatment group had positive PCR results for serum or oral swabs.   
 
 
Figure 5.2:SVA infection dynamics measured by RT-qPCR in A) rectal swabs, B) serum, and C) oral 
swabs collected during the study. Each inoculum dose is color coded 106.5 (red), 104.5 (orange), 102.5 
(green), and 100.5 (blue). Points on the graph represent the mean of the four animals and error bars and 
standard error of the mean.  
 
Virus neutralization titers were determined for 0 dpi and necropsy serum (14-15 dpi). All 
animals had titers ≤16 on 0 dpi. All animals from groups 106.5 and 104.5 developed neutralizing 
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titers ranging from 1024-4096 (Table 2). Two pigs in the 102.5 groups had titers of 64 and 1024 
respectively, while the remaining two pigs had titers less than 16. No pigs in the highest dilution 
seroconverted.    
In Study 2, SVA/CAN/2011 was serially ten-fold diluted to create six challenge 
inoculums for neonates with theoretical titers ranging between 105.5 to 100.5 TCID50/mL for the 
10-1 to 10-6 dilutions respectively (Table 3). The 10-1 to 10-3 dilutions had higher titers than the 
theoretical titer, but 10-2, 10-4, and 10-5 were the same as predicted. Again the 10-6 dilution was 
undetected by TCID50 assay. Inoculum Ct values ranged from 17.4-35.5 corresponding to 
1.28x108 to 570 GC/mL.   
Table 5.3: Titers, PCR Ct values, and GC/mL of virus dilutions used to inoculate neonatal pigs. 
* One of the three wells was undetermined so the value is an average of two wells. 
 
Due to the piglets being moved from individual animal housing to group housing on a 
deck, the 6 dpi samples collected as the animal was taken out of individual housing were the only 








105.5 10-1 316,000 501,000 17.4 1.28E+8 
104.5 10-2 31,600 31,600 20.9 1.13E+7 
103.5 10-3 3,160 5,010 25.1 6.39E+5 
102.5 10-4 316 316 28.7 5.75E+4 
101.5 10-5 31.6 31.6 32.3 5.12E+3 




samples used for PCR determination of infection status. In addition, the VN assay was performed 
on 10 dpi serum assuming piglets infected from pen mates once combined would not have 
enough time to develop a robust neutralizing antibody response. All four pigs in the 105.5 
treatment group were viremic, had detectable SVA in oral and rectal swabs, and seroconverted 
(Table 4). Only 2 pigs in the 104.5 treatment group had SVA positive serum and swab samples 
and a neutralizing antibody response. Both the 103.5 and 102.5 treatment groups only had 1 pig 
that had SVA positive samples; although, the pig in the 103.5 group had a neutralizing antibody 
response while the pig from the 102.5 group did not. All pigs in the 101.5 and 100.5 treatment 
groups tested negative for SVA and did not seroconvert. In addition, all the room control pigs 
were negative for SVA when removed from individual housing. 
Table 5.4: Summary of neonate PCR positive status for each sample type on 6 dpi and VN titer for 
10 dpi serum. 
 
Samples were also collected on 10 dpi and 14 dpi from all piglets while group housed to 
observe infection dynamics within each challenge group. All piglets including room controls 
from the 105.5, 104.5, 103.5, and 102.5 treatment groups were PCR positive in either serum or rectal 
swab collected on 10 dpi. By 14 dpi, viremia was detected in less animals, although most 
Inoculum Serum  Oral swabs Rectal swabs VN titer 
105.5 4/4 4/4 4/4 64, 256, 256, 1024 
104.5 2/4 2/4 2/4 ≤16, ≤16, 256, 1024 
103.5 1/4 1/4 1/4 ≤16, ≤16, ≤16, 1024 
102.5 1/4 1/4 1/4 ≤16, ≤16, ≤16, ≤16 
101.5 0/4 0/4 0/4 ≤16, ≤16, ≤16, ≤16 




animals in these groups still had positive rectal swabs. All piglets in the 101.5 and 100.5 treatment 
groups including room controls remained negative.  
  Tables 5 and 6 summarize the inoculum data with pig infection data. In finishing pigs 
inoculated with hundred-fold dilutions of SVA, the smallest dose that infected pigs was 1,260 
TCID50/mL (6,300 TCID50/pig). In this group, SVA was only detected in samples from one pig, 
but a neutralizing antibody response was detected in two pigs. This inoculum had a PCR Ct 
value of 26.5 and the next dilution that did not infect pigs had a Ct value of 32.6. In neonates 
inoculated with ten-fold dilutions of SVA, the smallest dose to infect piglets was 316 TCID50/mL 
(632 TCID50/pig). Although only one pig had PCR positive samples and had not developed a 
neutralizing antibody response by 10 dpi, the remaining piglets in the group became infected 
when the piglets were co-mingled. This inoculum had a PCR Ct value of 29.7 while the 
following dilution that did not infect pigs had a value of 33.2.    




TCID50/mL TCID50/pig Ct PCR positive VN positive 
5,010,000 25,550,000 11.0 4/4 (100%) 4/4 (100%) 
63,100 315,500 18.7 4/4 (100%) 4/4 (100%) 
1,260 6,300 25.6 1/4 (25%) 2/4 (50%) 




Table 5.6: Summary of SVA infection outcomes in neonatal pigs by PCR and VN assays. 
 
Discussion 
The main goal of this study was to determine the minimum infectious dose of SVA in 
both finishing pigs and neonatal pigs. Due to the size of market-weight pigs and the nature of the 
study, only one pig could be housed in a room at a time; therefore, only 4 hundred-fold dilutions 
were tested. The size of neonates and the ability to individually house all piglets for one dilution 
in the same room allowed for a greater range of dilutions to be tested, 6 ten-fold dilutions. 
Therefore, even though the minimum infectious dose of market weight pigs (1,260 TCID50/mL) 
was a higher titer than neonates (316 TCID50/mL), it does not necessarily mean that neonatal 
pigs have a lower threshold. Now that this study has helped narrow the window of the minimum 
infectious dose in finishing pigs, further research with ten-fold dilutions could provide a more 
precise estimate.     
None of the market-weight pigs that replicated virus and seroconverted developed 
vesicular lesions in this study. The same isolate given to 5-month-old pigs at a dose of ~1x107 
TCID50/mL did result in the development of lesions in 6/8 pigs (Buckley et al., unpublished). It 
TCID50/mL TCID50/pig Ct PCR positive VN positive 
501,000 1,002,000 18.3 4/4 (100%) 4/4 (100%) 
31,600 63,200 21.9 2/4 (50%) 2/4 (50%) 
5,010 10,020 26.1 1/4 (25%) 1/4 (25%) 
316 632 29.7 1/4 (25%) 0/4 (0%) 
31.6 63.2 33.2 0/4 (0%) 0/4 (0%) 




remains unclear why some animals develop lesions after exposure to SVA, while others do not. 
Although it was not observed in this study, one contributing factor could be inoculum dose. Most 
animals in experimental infection studies develop lesions, which could be attributed to the high 
doses of virus typically used for inoculation (107-108 TCID50) versus what may be lower levels 
during natural exposure (9-12, 23, 24). Reports of the incidence of vesicular lesions in the field 
have ranged from 10-90% of animals on affected farms (6, 25-27). In addition, lesion 
development may vary based on pathogenicity of the viral isolate. A recent study compared the 
pathogenesis of two Chinese SVA isolates with a 96% nucleotide identity (29 AA changes). The 
2016 isolate most similar to contemporary Canadian isolates did not result in any clinical 
disease, while the 2017 isolate similar to US strains did result in vesicular lesions in finishing 
pigs (28).    
SVA was first detected in rectal swabs of finishing pigs from the 106.5 group on 1 dpi 
with the 104.5 group following on 4 dpi and finally the 102.5 group on 7 dpi. In addition, the 
duration of PCR positive rectal swabs was correlated with dose as supported by the 106.5 group 
shedding for 12 days, the 104.5 group around 7 days, and the 102.5 group for 2 days. Some of these 
trends were also observed in the PCR result from serum and oral fluids. These PCR results 
support the SVA dose an animal is exposed to may affect the infection dynamics including viral 
replication and shedding. The inoculum dose and route of exposure of FMDV in swine affects 
the incubation period and infection dynamics with greater doses shortening the incubation period 
and decreasing time to clinical signs (29-31). Therefore, biosecurity measures in the field to 
decrease viral exposure could aide in reducing the severity of infection and spread on the farm.     
The four rooms housing finishing pigs in Study 1 were reused for each challenge dose 
starting with the highest dilution (100.5) and finishing with the lowest dilution challenge group 
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(106.5) due to animal housing constraints. In between challenge groups, rooms were washed 
down, treated with Virkon™ S and allowed to dry twice, and rinsed with water. PCR negative 
environmental swabs of gating in the room supported the efficacy of the cleaning and 
disinfection process for rooms between usage. Other disinfection produces including accelerated 
hydrogen peroxide and bleach have shown efficacy against SVA (32, 33). A positive 
environmental swab from a room housing a pig in the 106.5 group occurred right after the peak of 
SVA detection in rectal swabs; however, the remaining samples all tested negative suggesting 
there was not a high load of SVA in environment of these rooms. One explanation for lack of 
SVA detection in the environment of this study could be individual animal housing and is not 
representative of the load that may be present in a barn filled with infected animals.  
Field reports from SVA affected breeding herds have described increased neonatal 
mortality in piglets during the first week of life and the syndrome was termed epidemic transient 
neonatal losses (ETNL) (5, 25, 27, 34). Clinical signs observed included lethargy, wasting, and 
diarrhea with cases in Brazil also reporting neurologic signs and vesicular lesions (15, 25). Most 
cases of neonatal mortality in the US did not observe significant gross or histologic lesions in 
affected piglets (34). In contrast, Brazil reported histologic lesions including interstitial 
pneumonia, myocarditis, glossitis, atrophy of intestinal villi, ballooning degeneration of the 
transitional epithelium in the bladder, and encephalitis (15). Immunohistochemistry 
identification of SVA in histologic lesions of the bladder, intestines, and central nervous system 
plus PCR testing to rule out other viral agents provided evidence that SVA was the causative 
agent for these lesions in neonates (13, 35). Piglets in Study 2 were between 2-4 days-of-age 
when inoculated with SVA and the only clinical sign observed some piglets across all challenge 
groups was soft stool during the first week after infection. Although SVA cannot be ruled out in 
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the pigs that were PCR positive for SVA, the change of diet from sow’s milk to milk replacer 
likely played a role in the change in stool consistency. Thus, neonatal mortality due to SVA 
infection in breeding herds has yet to be experimentally reproduced and further research should 
be performed to better understand the contributing factors to ETNL.  
Dose effect on acute infection dynamics in the neonates could not be evaluated in this 
study since small ports on the cages were only opened for feeding during individual housing. 
Cage doors were not opened to sample animals due to the risk of virus contamination in the room 
and exposure of animals to virus beyond the dose received during inoculation. The negative PCR 
status of the sentinel pig in each challenge room supported that neonates were only exposed to 
the inoculum dose of SVA. The first samples collected from the neonates was on 6 dpi when 
animals were removed from individual housing and those were used to determine PCR positive 
status. PCR data collected after 6 dpi could not be used for infection status since it could be 
confounded by exposure to shedding from other infected animals in the group housing, but that 
information was critical to shedding light on the infectivity of positive pigs. For example, PCR 
results from the 102.5 group showed that four pigs (3 inoculated and 1 room control) negative for 
SVA on 6 dpi became positive on 10 dpi after contact with the one PCR positive pig from 6 dpi. 
Epidemiologic investigations conducted on SVA affected breeding farms subjectively 
assessed that indirect transmission of SVA through contaminated farm employees, livestock 
trailers or carcass removal equipment were likely routes of virus introduction (25). 
Environmental sampling to determine level of SVA contamination is most often tested by PCR. 
Limited information is available to correlate SVA PCR Ct values to infectious virus. In this 
study, the minimum infectious dose for finishing pigs had a Ct value of 25.6 and neonates 29.7. 
Again, only hundred-fold dilutions were tested on finishing pigs, so the true minimum infectious 
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dose may have a higher Ct value. Inoculum Ct values of 32.6 and 33.2 for finishing pigs and 
neonates respectively were not able to infect pigs. Environmental samples with Ct values around 
32 or greater may not present a large risk for infecting pigs and spreading SVA.  
This study determined the minimum infectious dose of a 2011 SVA isolate after 
intranasal inoculation in finishing pigs and oral inoculation in neonates. Differences in the 
dilution series and inoculation route could have contributed to differences in the minimum 
infectious dose between finishing pigs and neonates (29).  Recent studies have focused on more 
natural routes of exposure to determine minimum infectious dose such as oral exposure using 
natural feeding and drinking behaviors and pig-contact exposure (31, 36). In addition, other SVA 
isolates such as more contemporary strains may have different infectious doses. Information 
from this work can be used in future research to make more precise estimates of the infectious 
dose SVA with other strains and exposure routes. Understanding the minimum infectious dose of 
SVA can help producers and veterinarians in the swine industry focus their disease control and 
biosecurity measures on areas that carry the most risk of exposure of high levels of SVA.   
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Abstract 
Senecavirus A (SVA), commonly known as Seneca Valley virus (SVV) is a causative 
agent for vesicular disease in swine. It has been found across the globe including the United 
States, Brazil, and China. Clinical disease caused by this virus is identical to foot-and-mouth 
disease virus (FMDV). Since FMDV has the potential to cause severe economic consequences in 
FMDV-free countries, those countries are on high alert for signs of vesicles in swine and an 
investigation is performed to rule out the presence of FMDV if observed. In countries where 
SVA cases have continued to occur, investigations and testing can cause a burden on personnel 
and resources. The objectives of this study were to test the efficacy of a whole-virus inactivated 
SVA vaccine against challenge in nursery-aged pigs and mature sows, and to assess the 
protection of passive maternal immunity generated by immunized dams. Pigs were given two 
doses of the vaccine intramuscularly three weeks apart and challenged intranasally two weeks 
after the second dose. Non-vaccinated pigs challenged with SVA developed clinical signs of 
disease, replicated virus, and developed a neutralizing antibody response. Vaccinated pigs had 
robust neutralizing titers after two doses; and after challenge, did not develop vesicular disease 
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and had limited rectal shedding. Piglets suckling immunized dams and challenged with SVA at 
3-6 days-of-age had neutralizing titers prior to challenge and did not replicate or shed virus. An 
efficacious vaccine could improve swine welfare and reduce the economic consequences of 
continued foreign animal disease investigations. 
 
Introduction 
Senecavirus A (SVA) was first discovered as cell culture contaminant in 2002 (1). 
Retrospectively, testing of swine samples at the National Veterinary Services Laboratory had 
previously discovered a similar picorna-like virus in swine samples dating back to the late 1980s 
from various locations in the Unites States (US) and clinical histories (2). The speculation of the 
cell culture contamination being due to porcine trypsin (3) and presence of this virus in swine 
samples lead to the hypothesis that swine were the natural host (2). Early attempts to 
experimentally inoculate pigs with the virus did not result in specific clinical disease though 
some reported the virus did replicate in pigs (4, 5).  
SVA is a non-enveloped, single-stranded, positive-sense RNA virus (~7.2 kb) that is the 
only member of the genus Senecavirus in the family Picornviridae (1). Other swine viruses in 
the family Picornaviridae include foot-and-mouth disease virus (FMDV), swine vesicular 
disease virus (SVDV), and encephalomyocarditis virus. Of the picornaviruses, SVA has been 
found to be most closely related to cardioviruses (6). SVA has one large open reading frame that 
encodes a single long polyprotein cut by viral proteases in the standard L-4-3-4 format of 
picornaviruses resulting in 12 mature proteins: leader protein, VP4, VP2, VP3, VP1, 2A, 2B, 2C, 
3A, 3B, 3C, 3D (1). The structural proteins, VP1-4, form protomers that make up the icosahedral 
capsid of the virion. It has a long 5’ UTR that contains an internal ribosome entry site with a 
secondary structure that most resembles classical swine fever virus (5). 
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Late 2014 and into 2015, Brazil had a spike in idiopathic vesicular disease cases and 
increased neonatal mortality documented in the first week of life (7). Samples collected from 
these farms tested PCR positive for SVA (8). Shortly after, the United States saw similar cases of 
vesicular disease and neonatal mortality attributed to SVA starting the summer of 2015 (9-11). 
Contrary to attempts in the past, multiple groups were able to experimentally reproduce clinical 
disease in pigs of various ages demonstrating that SVA is a causative agent for vesicular disease 
in swine (12-14). Subsequently, other countries including Canada (15), China (16), Colombia 
(17), Thailand (18), and Vietnam (19) reported vesicular disease cases due to SVA. Including 
historical isolates, SVA strains from around the world share a nucleotide similarity of 93% or 
greater (20).  
There are multiple viruses that infect swine and cause vesicular disease including: SVA, 
FMDV, SVDV, vesicular stomatitis, and vesicular exanthema of swine. The clinical disease 
caused by each of these viruses is grossly identical and further diagnostics must be performed to 
differentiate the cause of disease (8). Differentiating the cause of vesicular disease in swine is 
important, because foot-and mouth disease (FMD) caused by FMDV is on the World 
Organization for Animal Health (OIE) list of notifiable diseases (21). For countries with FMD 
negative status, identifying a case of FMD would have severe economic ramifications including 
production loss, trade restrictions, and cost of regaining FMD-free status (22). With more FMD-
free countries identifying SVA, there is also an economic impact of an investigation to rule out 
FMDV every time an animal with vesicular disease is identified. A vaccine for SVA could 
reduce the occurrence of SVA-related vesicular disease thus improving swine welfare and reduce 
the economic burden of an endemic vesicular disease in FMD-free countries. 
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Research groups have previously shown the efficacy of a live-attenuated vaccine (23) and 
an inactivated vaccine (24) for protection against clinical disease of SVA in weaned pigs and 
finishing pigs respectively. To date, there have been no published studies evaluating vaccines in 
mature animals, though many reported cases of SVA vesicular disease occurred on sow farms 
with vesicular disease in sows and increased neonatal mortality (7, 11). The objectives of this 
study were to evaluate efficacy of an inactivated SVA vaccine in weaned pigs and mature sows, 
and the protection provided by maternal immunity from immunized dams.  
  
Materials and Methods 
Ethics statement 
The animal work in this study was performed under approved animal care and use 
protocols (ARS-2867, ARS-2019-793) by the National Animal Disease Center’s Institutional 
Animal Care and Use Committee. All animals were euthanized at the end of the study with an 
intravenous administration of a barbiturate (Fatal Plus, Vortech Pharmaceuticals, Dearborn, MI) 
following the label dose (1 mL/4.54kg). 
Virus inactivation and vaccine formulation  
A SVA strain isolated in 2015 from a clinical case of vesicular disease in pigs from Iowa 
(SVA/2015/IA) was propagated on swine testicular cells cultured at 37 °C and 5% CO2 in 
minimum essential medium (MEM) supplemented with 2.5% HEPES (Gibco). Twenty-four 
hours after cell cultures were inoculated, supernatant was collected and clarified by 0.2 µM 
filtration. Pre-inactivation the virus titer ranged between 8.6-8.9 log TCID50/mL. Binary 
ethylenimine (BEI) in addition to formalin were used to ensure inactivation of the virus. Material 
was neutralized with sodium thiosulfate and sodium bisulfite. Inactivation was confirmed by 
multiple passages in cell culture.  
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Inactivated virus was mixed with an oil-in-water adjuvant at 12.5%. Antigen and 
adjuvant were mixed for 30 min at room temperature and stored at 4°C prior to use. Vaccine was 
mixed gently directly prior to being drawn up into syringes for administration.  
Challenge viruses 
A SVA strain was isolated from a clinical case of vesicular disease in finishing pigs from 
South Dakota in 2015 (SVA/SD/2015). The isolate was propagated on a swine testicular (ST) 
cell line cultured at 37 °C and 5% CO2 in Minimum Essential Medium (MEM, MilliporeSigma, 
St. Louis, MO) supplemented with 10% FBS (AtlantaBio, Flowery Way, GA), gentamicin 
(VetOne/MWI, Boise, ID) and L-glutamine (Life Technologies, Carlsbad, CA). The virus was 
passaged 4 times in cell culture and was diluted to a titer of 1x107 TCID50/mL with MEM. 
Titrations were calculated using the Reed and Meunch method (25). 
A second SVA strain was isolated from piglet intestine from a farm experiencing 
vesicular disease in sows and an increased neonatal mortality (SVA/KS/2018). Again, this isolate 
was propagated on ST cells. The isolate was passaged 3 times in cell culture and was diluted 
with MEM into two stocks for inoculation: 1x107 TCID50/mL and 1x105 TCID50/mL. 
Animal studies   
Study 1: Forty-six pigs were farrowed on-site at the National Animal Disease Center 
(NADC) in Ames, IA and housed under ABSL-2 conditions for the experiment. At weaning, pigs 
were randomly ear tagged and assigned to 4 treatment groups: control (n=8), vaccinated (vax) 
(n=8), challenge (n=15), and vax+challenge (n=15). At three weeks of age, the vax and 
vax+challenge treatment groups were immunized intramuscularly in the right side of the neck 
with 2 mL of inactivated SVA (SVA/IA/2015) plus adjuvant. A second dose was given 
intramuscularly on the left side of the neck (2 mL) three weeks later. At 0 days post challenge 
(dpc) animals in the challenge and vax+challenge groups were intranasally challenged with 5 mL 
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of SVA/SD/2015 (1x107 TCID50/mL) divided between both nostrils (Table 1). Pigs were bled on 
-35, -14, 0, 3, 5, 7, 14 and 21 dpc. Group oral fluids and individual rectal swabs were collected 
daily from 0-10 dpc and on 14 and 21 dpc from challenged animals. Animals were euthanized on 
21 dpc.   
Study 2: Twenty sows were purchased from a commercial source in the Midwest of the 
United States and transported to the NADC. All animals were clinically free of lesions at the 
start of the study. Sows were bred via artificial insemination and 18/20 sows were confirmed 
pregnant by ultrasound. The two open sows were placed in the vax+challenge group while the 
remaining sows were randomly assigned to 4 groups: control (n=3), vax (n=3), challenge (n=5), 
and vax+challenge (n=9). At -35 dpc (~70 days of gestation) sows in the vax and vax+challenge 
treatment groups were immunized intramuscularly in the right side of the neck with 2 mL of 
inactivated SVA (SVA/IA/2015) plus adjuvant. A second dose was given intramuscularly on the 
left side of the neck (2 mL) three weeks later. At 0 dpc (~104 days of gestation) animals were 
separated into ABSL-2 rooms based on treatment and intranasally challenged with 5 mL of 
SVA/KS/2018 (1x107 TCID50/mL) split between both nostrils (Table 1). Challenged sows were 
bled on -35, -14, 0, 3, 7, and 14 dpc and rectal swabbed and observed for vesicular lesions on 0-
3, 5, 7, and 14 dpc. All sows were euthanized between 28 and 30 dpc.   
Study 3: Piglets born to control sows (n=3 sows, 41 piglets) and vax sows (n=3 sows, 24 
piglets) from Part 2 were challenged orally with 2 mL of SVA/KS/18 (1x105 TCID50/mL) while 
still suckling their dams (3-6 days of age) (Table 1). Piglets were ear notched for identification. 
They were bled on 0, 5, and 14 days post inoculation (dpi) and rectal swabbed on 0, 1, 2, and 5. 




Table 6.1: Experimental design of animal studies. 
Study Group N Vaccinea Timing Challenge Dose 
Study 1 Control 8 None  Sham  
 Vax 8 SVA/IA/2015 -35 and -14 dpc Sham  
 Challenge 15 None  SVA/SD/2015 5x107 TCID50 
 Vax+challenge 15 SVA/IA/2015 -35 and -14 dpc SVA/SD/2015 5x107 TCID50 
Study 2 Control 3 None  Sham  
 Vax 3 SVA/IA/2015 -35 and -14 dpc Sham  
 Challenge 5 None  SVA/KS/2018 5x107 TCID50 
 Vax+challenge 9 SVA/IA/2015 -35 and -14 dpc SVA/KS/2018 5x107 TCID50 
Study 3 Control sow litters 3   SVA/KS/2018 2x105 TCID50 
 Vax sow litters 3   SVA/KS/2018 2x105 TCID50 




 Vesicular lesions were scored with a 5-point system: each foot that displayed a vesicular 
lesion was given 1 point and a vesicle on the snout was assigned 1 point. An animal was given a 
score of zero if no lesions were identified. Scores were assigned on 0, 3, 5, 7, and 9 dpc/dpi. 
Total clinical score was calculated by adding up the scores for all pigs in the group. Finally, pigs 
were observed daily for clinical signs of lameness, lethargy, and inappetence.   
Blood was collected in serum separator tubes (BD Vacutainer®, Franklin Lakes, NJ) and 
centrifuged to harvest serum. Fecal swabs were collected using a sterile polyester tipped 
applicator (Puritan Medical Products, Guilford, ME), immersed in 3 mL of serum-free MEM. 
Oral fluids were collected with a white cotton rope hung for a half hour at pig level in each pen 
containing all pigs in the treatment group. Liquid was manually squeezed from the rope into a 
plastic bag and poured into vials for storage. All samples were stored at -80°C for future testing.  
SVA nucleic acid quantification 
Serum, swabs, and oral fluid samples were extracted and tested by real time RT-qPCR as 
previously described (26). Briefly, RNA was extracted from samples using the MagMAX™ 
Pathogen RNA/DNA kit (catalog no. 4462359; Applied Biosystems). Next, 5 µL of extracted 
product was added to 20 µL of the Path-ID™ Multiplex One-Step RT-PCR reaction master mix 
(Applied Biosystems) for fecal swabs and oral fluids or 20 µL AgPath-ID™ One step RT-PCR 
master mix (Applied Biosystems) for sera and vesicle swabs. The forward primer sequence was 
5’-TGCCTTGGATACTGCCTGATAG-3’, the reverse primer sequence was 5’-
GGTGCCAGAGGCTGTATCG-3’ and the probe sequence was 5’-
CGACGGCCTAGTCGGTCGGTT-3’. RNA copies were calculated based on a standard curve 




Virus neutralization (VN) assay 
The virus neutralization assay has previously been described (26). In brief, serum 
samples were heat-inactivated at 56 °C for 30 min, serially diluted 1:4 (up to 1:4096) in MEM 
and repeated in quadruplicate. An equal volume of diluted challenge virus, SVA/SD/15 or 
SVA/KS/18, (~200 TCID50) was added to the serum and incubated for 1 hour. The virus-serum 
mixture was transferred to 96-well plates of ST cells. Plates were microscopically evaluated for 
cytopathic effect (CPE) daily for 4 days. Titers were recorded as the reciprocal of the highest 
dilution of serum at which the infectivity of the SVA isolate was completely neutralized in 50% 
of the inoculated wells. Virus neutralization titers of ≤16 were considered negative. 
Statistical analysis 
Statistical analysis was performed by multiple t-tests without the assumption of 
consistent standard deviation (SD). Multiple comparisons were corrected using the Holm-Sidak 
method with alpha = 0.5. Statistical analysis and graphs were performed and prepared using 




Two groups of animals were sham challenged. The control pigs did not develop clinical 
signs of vesicular disease, SVA RNA was not detected in any sample tested by PCR, and pigs 
did not seroconvert with neutralizing antibody titers of ≤16 at 21 dpc. In the vax group, no 
animals were observed with vesicular lesions and SVA RNA was not detected in tested serum, 
rectal swabs, or oral fluids after sham challenge. After the first dose of vaccine, 3/8 animals had 
titers greater than 16. Following two doses of vaccine, all animals (8/8) in the vax group 





Figure 6.1: Virus neutralization titers. VN titers from serum collected in Study 1 against SVA/IA/2015 
(A), and against SVA/KS/2018 in Study 2 (B) and Study 3 (C). The mean titer for the challenge group is 
represented by red bars, the vax+challenge group by blue bars, the vax group by purple bars, and the 
control group by green bars (A and B). Mean titers for piglets born to control sows is colored green and 
data from piglets born to vaccinated sows is colored purple (C). Error bars represent SD.   
Two groups were intranasally challenged with SVA/SD/2015. In the challenge group, 
12/15 animals developed vesicular lesions after challenge (Figure 2A). Lesions were first 
observed on 3 dpc with vesicle development on the coronary bands of 2 pigs and the peak 
number of animals observed with lesions occurred on 7 dpc. Snout lesions were not observed 
until 5 dpi with a total of 5/15 animals eventually developing erosions on the snout. The 
vax+challenge group did not develop any signs of vesicular disease following challenge. 
 SVA RNA was detected in rectal swabs by 1 dpc in both the challenge (12/15) and 
vax+challenge (13/15) pigs (Figure 2B). However, all animals in the vax+challenge group were 
negative by 2 dpc and remained negative for SVA by PCR in rectal swabs until the end of the 
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study. In contrast, SVA RNA was detected in rectal swabs from the challenge group from 1 dpc 
until the end of study (21 dpc) with 9/15 (60%) of pigs with a positive rectal swab at necropsy. 
There was a decrease in SVA detection in this group between 8 and 10 dpc, but genomic copies 
increased again by 14 dpc. SVA RNA was detected in serum in most animals (13/15) in the 
challenge group during the first week after challenge, with two animals that did not develop a 
measurable viremia (Figure 2C). No virus was detected in serum from the vax+challenge group. 
Similar to the serum PCR results, oral fluids demonstrated viral detection in the challenge group, 
but not in the vax+challenge group (Figure 2D). Viral levels in the oral fluids remained similar 
throughout the study.  
 
Figure 6.2: Clinical scores and virual load as determined by RT-qPCR in Study 1. A) Ruptured 
coronary band lesion observed in a challenged pig and a snout erosion observed on a challenge pig on 7 
dpi. Animals were scored on a scale of 0-5. Scores were added up for each group and the total clinical 
score plotted. The mean log10(genomic copies/mL) for challenge pigs and vax+challenge pigs in rectal 
swabs (B) and serum (C). Error bars represent SD (**P < 0.01; ***P < 0.001; ****P < 0.0001). The 
log10(genomic copies/mL) of oral fluids collected from each group. Challenge pig data colored red and 




All animals in the challenge group started with a VN titer ≤16 prior to challenge (0 dpc) 
and at 21 dpc VN titers ranged from 1:64 to 1:256 (Figure 1A), except one animal with a titer of 
1:16. The pig with a titer of 1:16 was also one of the two pigs that did not have a detectable 
viremia; although, this animal did have positive rectal swabs throughout the study. Similar to the 
vax group, 7/15 animals in the vax+challenge group had VN titers greater than 16 after the first 
dose of vaccine. Prior to challenge, all animals in the vax+challenge group but one had titers 
greater than 16 following two doses of vaccine (0 dpc). At the end of the study (21 dpc), titers in 
the vax+challenge group ranged from 1:64 to 1:1024 which was similar to those animals in the 
challenge group (Figure 1A).  
Study 2 
Two groups of sows were sham challenged. Control sows did not develop clinical signs 
of vesicular disease, SVA RNA was not detected in any sample tested by PCR, and pigs did not 
develop a neutralizing antibody response with titers ≤ 16 at the end of the study. In the vax 
group, no animals were observed with vesicular lesions and SVA RNA was not detected in tested 
serum or rectal swabs after sham challenge. Animals in the vax group had VN titers ranging 
from 64 to 256 following one dose of vaccine (-14 dpc) and 256 to 1024 after two doses of 
vaccine (0 dpc) (Figure 1B).  
Two groups were intranasally challenged with SVA/KS/18. In the challenge group, 2/5 
animals developed vesicular lesions on their snouts (Figure 3A). No lesions were observed on 
coronary bands. The vax+challenge group did not develop any signs of vesicular disease 
following challenge. SVA RNA was first detected in two rectal swabs from both the challenge 
group (2/5) and the vax+challenge (2/9) group on 5 dpc (Figure 3B). The remaining rectal swabs 
were negative by PCR. SVA RNA was detected in the serum of two animals in the challenge 
group on 3 dpc (Figure 3C). In contrast, SVA was not detected in the serum from any animals in 
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the vax+challenge group. In general, low levels of SVA were detected by PCR after challenge 
and there was no significant difference between the two groups in rectal swabs or serum. In total, 
SVA RNA was detected by PCR in one sample, either serum, rectal swab, or vesicular swab in 
4/5 animals in the challenge group and only 2/9 animals in the vax+challenge group.  
 
Figure 6.3: Clinical scores and viral load as determined by RT-qPCR in Study 2. A) Intact vesicle on 
the snout of a challenged sow at 8 dpi and the same lesion ruptured and healing on 14 dpi. B) Animals 
were scored on a scale of 0-5. Scores were added up for each group and the total clinical score plotted. 
The mean log10(genomic copies/mL) for challenge pigs and vax+challenge pigs in rectal swabs (C) and 
serum (D). Error bars represent SD. Challenged pig data colored red and vax+challenge pig data colored 
blue.   
All animals started with a VN titer ≤ 16 prior to challenge (0 dpc). VN titers ranged from 
1:1024 to 1:4096 in the challenge group at necropsy (Figure 1B). The vax+challenge group had 
VN titers ranging between 16 and 64 after one dose and from 64 to 1024 following two doses of 
vaccine (0 dpc). At the end of study, titers in the vax+challenge group remained between 64 and 
1024. There was no significant difference in titers between the challenged and vaccinated 
animals at necropsy. Though animals in the challenge group had limited amounts of shedding 
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detected by PCR, all seroconverted after challenge and developed a robust neutralizing antibody 
titer.  
Study 3 
Control sows (n=3) and vax sows (n=3) farrowed and all piglets were challenged orally 
with SVA/KS/2018 around 3-6 days of age, while remaining with the sow. No clinical signs 
were observed in any of the piglets, except 2-3 piglets with a mild transient diarrhea in litters 
born to both control sows and vax sows. All piglets born to control sows were positive for SVA 
by PCR in serum samples collected on 5 dpi (42/42). A few piglets had positive 1 and 2 dpi 
rectal swabs; however, by 5 dpi 29/42 piglets had a PCR positive rectal swab. Piglets born from 
vaccinated sows did not have any PCR positive serum or rectal swabs after challenge (0/24). 
The first four ear notched piglets were selected from each litter for VN testing on 0 and 
14 dpi serum (Figure 1C). Prior to challenge, piglets tested from control sows had neutralizing 
titers ≤ 16. After challenge (14 dpi) piglets seroconverted with neutralizing titers from 256 to 
4096. In contrast, piglets born to vaccinated sows had neutralizing titers ranging from 256 to 
1024 prior to challenge due to suckling vaccinated sows. After challenge, VN titers decreased in 
most piglets and ranged from 16 to 1:1024, which follows waning maternal immunity.  
 
Discussion 
Vaccines play a critical role in the prevention and control of viral and bacterial diseases 
of swine (27). Inactivated whole-virus vaccines do not replicate in the host; therefore, they do 
not cause clinical disease and there is no potential to revert back to a virulent strain like live-
attenuated vaccines. Inactivated vaccines have been proven to be safe and efficacious for viral 
diseases in swine (28). In this study, a whole-virus SVA inactivated vaccine was given in two 
doses to weaned pigs and sows and its efficacy against SVA challenge was evaluated. In 
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addition, maternal immunity provided by vaccinated sows was assessed by challenging suckling 
piglets.     
Weaned pigs have previously been utilized for a SVA vaccine efficacy study and animals 
given two doses of an inactivated SVA vaccine and challenged with a heterologous SVA isolate 
developed viremia, shed virus detected by PCR in rectal, oral, and nasal swabs, and developed 
vesicular lesions (23). In contrast, vaccinated pigs in study 1 did not develop clinical disease, did 
not have a detectable viremia, and viral nucleic acid was only detected in rectal swabs on 1 dpc 
after challenge. It is likely this material was pass-through from the intranasal inoculation, but 
minor replication within the pig cannot be ruled out. Both studies used animals close in age and 
the inactivation process and adjuvant were similar, but the challenge virus in study 1 more 
closely matched the vaccine isolate with a 99.2% nucleotide identity of the whole genome 
compared to 97% nucleotide identity between the vaccine and challenge isolates in the previous 
study (23). In addition, Sharma et al. used a challenge dose of 1x108.5 TCID50 in 10 mLs given 
oronasally (23), while the challenge dose in this study was 5x107 TCID50 in 5 mLs given 
intranasally. Both the use of a more genetically dissimilar challenge isolate and a higher 
challenge dose could explain the difference in vaccine efficacies observed between these two 
studies.  
Another study tested the efficacy of an inactivated SVA vaccine, but utilized finishing 
pigs rather than weaned pigs (24). In the other study pigs only received one dose of inactivated 
SVA vaccine prior to being challenged with 3x109 TCID50 and pigs were protected from the 
development of clinical disease and did not develop viremia after challenge, but further samples 
such as rectal/nasal swabs were not collected to look for viral shedding (24). The virus used for 
vaccination was the same virus used to challenge the pigs thus more likely to be effective than 
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versus a heterologous challenge. After two doses, vaccinated pigs in both study 1 and 2 had 
similar VN titers to non-vaccinated challenged pigs. Further work would need to be performed to 
evaluate if one dose would have been sufficient to provide protection.  
Based on the success in Study 1, Study 2 was performed with mature sows since they 
may be the more likely candidate for vaccination. The cull sow network, which can include 
multiple collection points and trucking over large distances to group sows for slaughter plants, 
has been recognized as a disease transmission risk (29). In the US, sows with vesicular lesions 
have been observed on a regular basis when arriving at sow slaughter plants (J. Korslund, 
personal communication), thus vaccinated sows prior to entering the cull sow market could 
reduce or prevent the number of foreign animal disease (FAD) investigations occurring at sow 
slaughter plants. In 2018 there were 2,072 FAD investigations in the US with 1,592 involving 
vesicular disease conditions in pigs (30). These investigations are costly in terms of both time 
and resources to rule out FMDV every time a vesicle is observed on a pig.  
This was the first time SVA/KS/18 was used to challenge swine after isolation and PCR 
results in mature animals showed limited viral replication. Based on results of the challenged 
sows, there was very little detectable virus in either the serum or swab samples collected, which 
makes it difficult to show reduction of viral replication and shedding between the challenge 
group and the vax+challenge group. Evidence that the challenge virus was recognized despite 
limited PCR detection was the robust neutralizing antibody response generated by animals in the 
challenge group. In addition, 2/5 challenge animals did develop vesicles on their snouts that 
contained high levels of virus by PCR. Experimental SVA challenge work with sows is limited, 
but another study using sows reported 4/5 sows developed vesicular lesions after challenge and 
field observations at sow farms experiencing SVA outbreaks have reported a large range in the 
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percentage of sows observed with vesicular lesions (11, 31, 32). Thus, it could be expected that 
not all sows develop lesions after challenge. Overall, the lack of lesion development in all nine 
animals of the vax+challenge group compared to lesion development in 2/5 challenged animals 
provides support that the vaccine protects against the development of vesicular disease in mature 
animals. Further evaluation of this vaccine in mature animals should be performed with another 
challenge strain to evaluate difference in viral replication and shedding. 
 Study 3 evaluated if the inactivated SVA vaccine given to sows could provide 
protection to nursing piglets challenged with SVA. In the field, there have been multiple reports 
of increased neonatal mortality in piglets less than 1 week of age that tested positive for SVA 
(11, 33, 34). Piglets have been reported with clinical signs including lethargy, diarrhea, and 
neurologic signs (35). Piglets challenged between 3-6 days of age after suckling control sows did 
not develop any clinical signs beyond a mild transient diarrhea in 2-3 piglets, which was also 
observed in piglets suckling vaccinated sows. Challenged piglets replicated virus and SVA was 
detected in both serum and rectal swabs. The pre-weaning mortality observed in this study was 
12% for control sow litters and 4% for vax sow litters. The mean piglet pre-weaning mortality 
rate in commercial swine herds ranges between 10% and 20% (36) and the pre-weaning 
mortality during outbreaks in the field have been reported to be up to 60% (32). Although the 
control litters had a higher percentage of pre-weaning mortality compared to the vax litters, it 
still falls within the commercial norm. In addition, the larger litter sizes in the control sows litters 
(n=14, 14, 13) versus the vax sow litters (n=9, 9, 6) may have contributed to the higher pre-
weaning mortality in this study. 
Piglets born to vaccinated sows had VN titers measured in serum prior to challenge 
demonstrating that sows vaccinated around 70 days of gestation and boosted around 90 days of 
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gestation transferred immunity to their piglets. Negative PCR results supported that maternal 
immunity was able to protect piglets from SVA challenge. In contrast, piglets without immunity 
replicated virus and may be an important source of viral amplification during a SVA outbreak at 
a naïve farrowing facility.    
In the US when a vesicle is observed on a pig, animal movement is stopped while trained 
personnel initiate a FAD investigation requiring sample collection for shipment to both a 
National Animal Health Laboratory Network lab and the Foreign Animal Disease Diagnostic 
Lab to rule out FMD. These FAD investigations and sample testing are costly to both the 
industry and the government, especially if SVA continues to remain endemic in the US swine 
herd. In addition, with the consistent occurrence of vesicular lesions in swine, veterinarians and 
producers in the swine industry may become compliant in assuming lesions are due to SVA 
infection. If FMDV were to enter the country and remain undetected for a period, the 
consequences could be devastating for not only the swine industry, but also animal agriculture 
and the economy. An effective SVA vaccine would be a valuable tool for the swine industry that 
could have a positive impact on welfare and reduce the economic burden of investigating 
vesicular disease cases. 
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CHAPTER 7.    GENERAL CONCLUSION 
Research Summary 
Senecavirus A (SVA) was originally discovered as a cell culture contaminant in 2002, but 
similar picorna-like viruses had been found in swine samples in the US dating back to the 1980s. 
These isolates came from swine with various clinical histories, and experimental inoculation 
with swine did not result in specific clinical disease. SVA was detected sporadically until late 
2014, when outbreaks of vesicular disease and neonatal mortality in Brazil had samples test 
positive for SVA. Similar cases appeared in the US in 2015, and experimental inoculation with 
contemporary SVA isolates were successful in reproducing vesicular lesions supporting SVA as 
a causative agent for vesicular disease in swine.   
The main objective of this research was to better understand the pathogenesis of SVA in 
swine. The inability to reproduce clinical disease during initial attempts to experimentally infect 
swine with SVA led to speculation about the requirement of a co-factor or pathogenicity 
differences between strains. The early clinical history of lesions in pigs during marketing and 
traveling to fairs in the US drove our hypothesis that stress may exacerbate clinical disease in 
swine. To simulate stress, an immunosuppressive dexamethasone regime was administered to 9-
week-old pigs prior to SVA inoculation. Clinical disease was similar between dexamethasone 
treated pigs and non-treated pigs. In addition, viremia, viral shedding, and neutralizing antibody 
response was similar between groups. Thus, this study supported that stress was not required for 
lesion development and provided information about infection dynamics that could be used by 
veterinarians and producers to develop strategies for diagnostics and control of SVA in the field. 
To further explore infection dynamics and pathogenicity of different SVA strains, three 
historical isolates and three contemporary isolates were selected for comparison. There were 
140 
 
some apparent differences in timing of lesion development, viremia, and viral shedding, but all 
viruses replicated and caused vesicular disease in pigs. Serum from all pigs had cross-
neutralizing antibodies against all viruses in the study; but, cross-neutralizing titers against 
historical isolates were lower than contemporary isolates. Sequence analysis of the six isolates in 
this study showed amino acid changes in prominent loop structures of the capsid that may play a 
role in the differences observed in cross-neutralizing titers. The study was the first to 
demonstrate that the original cell culture contaminant SVA isolate could cause vesicular disease 
in swine.    
Experimental animal infections often use high titers of inoculum to ensure consistent 
replication of disease. Therefore, experimental infections may not be reflective of titers of virus 
swine are exposed to in the field. To better understand pathogenesis of SVA at different 
inoculum dosages and the infectious dose of SVA, serial hundred-fold dilutions and ten-fold 
dilutions of SVA were used to inoculate finishing pigs and neonates, respectively. In this study, 
with a 2011 SVA isolate, finishing pigs had a MID of 103.1 TCID50/mL and neonates 102.5 
TCID50/mL. Although the MID for finishing pigs was higher in this study, the use of hundred-
fold dilutions for inoculums provided a less precise estimate compared to the ten-fold dilutions 
used for neonates. This study also provided insight into the correlation of PCR Ct values with 
viral titers in cell culture and infectivity in swine. For example, swabs from vesicular lesions can 
contain titers of 106 TCID50/mL, so contact with a vesicle could expose pigs to virus 
concentrations 3 logs higher then what is necessary to infect a finishing pig.  
Vaccines play a critical role in the control and prevention of many veterinary diseases. 
The type of vaccine to be used is dependent on many factors that include safety, efficacy, and 
economy. Inactivated virus vaccines are often a safe and efficacious option that can be economic 
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to produce making this type of vaccine the initial choice to test. Two doses of a SVA inactivated 
vaccine prevented clinical disease and viremia and reduced viral shedding in rectal swabs in both 
weaned pigs and sows after challenge. In addition, passive maternal immunity from vaccinated 
sows appeared to provide sterile immunity to suckling pigs challenged with SVA. An effective 
vaccine could improve swine welfare and reduce the economic burden of FAD investigations.   
 These studies have provided critical information about the infection dynamics of various 
SVA isolates in swine and have demonstrated the efficacy of an inactivated vaccine against SVA 
challenge. If SVA remains endemic in FMDV-free countries, the burden of ruling out FMDV 
every time a vesicular lesion is observed in swine will remain. A better understanding of SVA 
pathogenesis, molecular evolution, and epidemiology is crucial to developing control and 
prevention measures for SVA in the global swine industry.  
Future Work 
Viral factors involved in pathogenicity of SVA and potential differences among strains 
are not understood. Future research utilizing reverse genetics could provide valuable information 
about individual protein functions and regions that may contribute to pathogenicity. Additional 
research to correlate PCR values, virus titration in cell culture, and infectivity with swine 
bioassay would help veterinarians make more educated decisions with PCR results. A follow-up 
infectious dose study in market-weight animals with ten-fold dilutions may provide a better 
estimate of the MID and help discern if there are age related differences in susceptibility to SVA 
infection. Finally, a vaccine study comparing the efficacy of one dose of an inactivated SVA 
vaccine to two doses would be beneficial to the swine industry. Not only is a one dose product 
easier to administer, but this study would also provide additional information about the 
neutralizing antibody titer required for protection.
 
